Nitisinone (MDK-Nitisinone) (MendeliKABS Inc.)
Indication: For the treatment of patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine
Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Table of Contents

Abbreviations .................................................................................................................. 5
Executive Summary .......................................................................................................... 6
  Introduction ..................................................................................................................... 6
  Results and Interpretation .............................................................................................. 7
  Conclusions ..................................................................................................................... 10
Introduction ...................................................................................................................... 13
  Disease Prevalence and Incidence ............................................................................... 13
  Standards of Therapy .................................................................................................... 13
  Drug ................................................................................................................................ 14
Objectives and Methods .................................................................................................. 15
  Objectives ...................................................................................................................... 15
  Methods .......................................................................................................................... 15
Results ............................................................................................................................... 17
  Findings From the Literature ...................................................................................... 17
  Included Studies ............................................................................................................. 19
  Exposure to Study Treatments .................................................................................... 24
  Critical Appraisal .......................................................................................................... 24
  Efficacy .......................................................................................................................... 27
  Harms .............................................................................................................................. 33
Discussion .......................................................................................................................... 35
  Summary of Available Evidence ................................................................................. 35
  Interpretation of Results ............................................................................................... 35
Conclusions ......................................................................................................................... 39
Appendix 1: Patient Input Summary .................................................................................. 40
Appendix 2: Literature Search Strategy ............................................................................. 43
Appendix 4: Validity of Outcome Measures ....................................................................... 46
Appendix 5: Bioequivalence Study ..................................................................................... 49
References .......................................................................................................................... 55
Tables
Table 1: Summary of Results ........................................................................................................... 11
Table 2: Inclusion Criteria for the Systematic Review ................................................................. 15
Table 3: Details of Included Studies ............................................................................................ 18
Table 4: Summary of Baseline Characteristics .......................................................................... 20
Table 5: Patient Disposition ........................................................................................................ 24
Table 6: Survival Probability ...................................................................................................... 28
Table 7: Liver Failure (n, %) ...................................................................................................... 29
Table 8: Liver Transplantation (n, %) ........................................................................................ 30
Table 9: Laboratory Variables .................................................................................................... 32
Table 10: Harms ........................................................................................................................... 34
Table 11: Survival Probabilities After 2, 4, and 6 Years of Treatment With Nitisinone (%) ....... 45
Table 12: ....................................................................................................................................... 51
Table 13: Summary Statistics of Pharmacokinetic Parameters ................................................ 52
Table 14: ....................................................................................................................................... 52
Table 15: Comparative Bioavailability Data for Single-Dose Nitisinone (10 mg) ................. 53
Table 16: ....................................................................................................................................... 54

Figure
Figure 1: Flow Diagram for Inclusion and Exclusion of Studies .................................................. 17
Abbreviations

AE  adverse event
AFP  alpha-fetoprotein
ALT  alanine trans
AUC  area under the concentration-time curve
CDR  CADTH Common Drug Review
CLF  Canadian Liver Foundation
CORD  Canadian Organization for Rare Disorders
C_{max}  maximum observed concentration
FAA  fumarylacetoacetate
FAH  fumarylacetoacetate hydrolase
HCC  hepatocellular carcinoma
HT-1  hereditary tyrosinemia type 1
MAA  maleylacetoacetate
SA  succinylacetone
SAA  Succinyl acetoacetate
SAE  serious adverse event
T_{max}  time of observed maximum observed concentration
### Executive Summary

#### Introduction

Hereditary tyrosinemia type 1 (HT-1) is a rare, autosomal recessive disorder of amino acid metabolism. The deficiency of fumarylacetoacetate hydrolase (FAH), which is the last enzyme in the pathway of tyrosine catabolism, results in the accumulation of toxic metabolites in the FAH-deficient hepatocytes and proximal renal tubular cells, and subsequently leads to liver and kidney damage. HT-1 typically manifests in infancy and is characterized by elevated plasma tyrosine levels. For children whose HT-1 is not detected by the newborn screening, liver dysfunction, such as bleeding abnormalities, hypoglycemia, ascites, edema, vomiting, irritability, and jaundice, is the dominant clinical manifestation. Progression of the liver disease can be chronic or acute, with rapid deterioration. The lifetime risk of developing hepatocellular carcinoma (HCC) is as high as 37% in the survivors without treatment, according to previous research. Many patients also suffer from neurocognitive deficits. If untreated, survival in patients with HT-1 is less than 12 months of life; most of these children die as a result of liver failure and severe coagulopathy. The prevalence of HT-1 ranges from one in 12,000 to one in 100,000 individuals of Northern European descent. In Canada, higher prevalence (one in 1,846 live births) was observed in the Saguenay–Lac Saint-Jean region in Quebec.

Newborn screening allows for earlier identification of the disorder and earlier intervention. Previous research suggests better outcomes when treatment begins at an asymptomatic stage. Detection of succinylacetone (SA) in urine, plasma, or amniotic fluid is considered pathognomonic of tyrosinemia, as SA is not found in any other condition. Province-wide newborn screening for tyrosinemia has been practised since 1970 in Quebec.

Without treatment, death in childhood is common. Before the introduction of nitisinone, the management of HT-1 involved dietary restriction of phenylalanine and tyrosine, along with supportive treatment, until liver transplantation if possible. At present, all affected children are managed with nitisinone in combination with a tyrosine- and phenylalanine-restricted diet. Liver transplantation remains the only definitive therapy for patients with HT-1, when the patients do not respond to nitisinone therapy and there is progressive liver failure, or they have suspected HCC. However, liver transplantation is associated with risks of...
operative complications, including death, graft rejection, and the challenge of organ availability.

Nitisinone (MDK-Nitisinone) is a competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase, an enzyme upstream of FAH in the tyrosine catabolic pathway. It prevents the accumulation of the catabolic intermediates, which can be converted to the toxic metabolites SA and succinyl acetoacetate. The effect of nitisinone on inhibiting catabolism of tyrosine also leads to an increase in plasma tyrosine levels. Therefore, treatment with nitisinone requires restriction of the dietary intake of tyrosine and phenylalanine to prevent tyrosine toxicity.

MDK-Nitisinone is supplied as capsules containing 2 mg, 5 mg, 10 mg, or 20 mg of nitisinone. The 20 mg strength of MDK-Nitisinone was approved by Health Canada while CADTH Common Drug Review (CDR) review was ongoing. Nitisinone was provided to Canadian patients as another product (Orfadin) beginning in 1994 by Swedish Orphan Biovitrum AB (Sobi), under the Health Canada Special Access Programme, which ended in late 2016. A Notice of Compliance for MDK-Nitisinone for the treatment of adult and pediatric patients with HT-1 in combination with dietary restriction of tyrosine and phenylalanine was granted by Health Canada on September 20, 2016. The recommended initial dosage of nitisinone is 1 mg/kg body weight per day, in two divided doses orally. The dose of nitisinone should be adjusted individually based on weight, biochemical, and enzyme markers. The maximum daily dose of nitisinone is 2 mg/kg.

MDK-Nitisinone received Health Canada approval based on the clinical studies for the reference product (Orfadin), which are the studies included in this review (below), and based on data demonstrating bioequivalence with Orfadin (see Appendix 5: Bioequivalence Study).

Results and Interpretation

Included Studies

Two manufacturer-submitted, single-arm, open-label studies (NTBC and Quebec studies) were included in this review to assess the clinical efficacy and safety of nitisinone in combination with dietary restriction of tyrosine and phenylalanine in patients with HT-1. The NTBC study enrolled patients from 25 countries, including Canada (39 patients), between February 1991 and August 1997. In the main analysis of the NTBC study, 207 patients received nitisinone at a starting dosage of 0.6 mg/kg/day to 1 mg/kg/day compared with a historical patient population that received dietary treatment alone (N = 108). A separate set of patients was subsequently enrolled, resulting in a complementary analysis performed on 250 patients who received nitisinone at the currently recommended starting dosage of 1 mg/kg/day (the main and complementary analyses shared about 150 patients enrolled in a common overlapping time period). The outcomes assessed included: survival, survival without need for liver transplantation, death due to liver failure, development of HCC, and porphyric crises, as well as biochemical variables of liver function, kidney function, hemic system, SA, and tyrosine.

In the Quebec study, a cohort of 78 patients from Quebec born between 1984 and 2004 was analyzed. This period encompasses the introduction of nitisinone to Canadian clinical practice in 1994. Patients were categorized according to their treatment experience: nitisinone-naive, nitisinone started before 30 days of age, and nitisinone started after 30 days of age. Newborn screening, restricted diet, and liver transplantation were available to
all patients, while patients in the nitisinone-treated groups also received nitisinone. Nitisinone was initially administered at 0.6 mg/kg/day or 1 mg/kg/day, and it was increased to 1 mg/kg/day after the first few years of the study. Nitisinone-treated patients were compared with those who did not receive nitisinone therapy. Survival probability, occurrence of liver failure, requirement of liver transplantation, development of HCC, porphyric crises, hospitalization due to acute HT-1-related complications, and biochemical variables related to HT-1 were examined.

The main limitation was that both studies were single-arm, and the clinical benefits and harms of nitisinone in combination with dietary restriction of tyrosine and phenylalanine were examined by comparison with a historical control. No formal statistical test was performed on the outcomes between treatment and control. No precise estimates of treatment effects of dietary restriction plus nitisinone relative to dietary restriction alone were produced. In addition, significant heterogeneity was observed between patients treated with nitisinone in combination with dietary restriction and the historical control (dietary restriction alone). Therefore, this renders it difficult to assess the benefit of nitisinone in combination with dietary restriction, although a protective effect on a series of pre-specified, clinically relevant, long-term outcomes, such as survival and liver and renal function, are highly likely. However, given the nature of such a severe, life-threatening, rare disease, such a single-arm trial design seems acceptable, particularly in light of the lack of any other maintenance treatment.

Efficacy

Survival probability was higher in patients treated with nitisinone compared with patients with dietary restriction alone (historical cohort). In the NTBC study, the two-year and four-year overall survival rates for patients who initiated nitisinone at any age ranging from zero to 24 months were 96% and 93%, respectively. For patients who started nitisinone before two months of age, their two-year and four-year overall survival rates were 88% and 88%, respectively. For those who started before six months of age, the two-year and four-year overall survival rates were 94% and 94%, respectively. For those who started after six months of age, the two-year and four-year overall survival rates were 97% and 93%, respectively. Results of the complementary analysis (at the recommended starting dosage of 1 mg/kg/day) were similar to those in the main analysis — the overall survival rate for patients who initiated nitisinone at any age was 93% at two years, four years, and six years. In the historical population that received dietary treatment alone, the two-year survival rates were 29%, 74%, and 96% for patients in whom symptoms developed before two months, from two months to six months, and after six months of age, respectively. The four-year survival rate was similar to the two-year survival rate in the historical population for all three subgroups of patients. In the Quebec study, higher survival rates were observed in patients treated with nitisinone (100%) compared with those who never received nitisinone treatment (71%) before liver transplantation.

Patients treated with nitisinone had a lower risk of death or transplantation due to liver failure. In the NTBC study main analysis, 14 patients (6.8%) died or received transplants due to liver failure: seven (3.4%) died and seven (3.4%) underwent transplantations. For patients whose treatment started before six months of age, 9% (seven of 80 patients) died of liver failure or were transplanted due to liver failure. In the historical control, 30% of patients died or were transplanted due to liver failure: 25% died, and 6.4% received transplants. According to the European Medicines Agency report, for patients in the historical cohort with symptom onset before six months, 42% died of liver failure or
recurrent bleeding with or without liver failure (data were only reported with recurrent bleeding). The results imply that treatment with nitisinone reduces the risk of fatal liver disease in patients presenting symptoms before six months of age with the acute form of HT-1. In the Quebec study, none of the patients who started nitisinone before 30 days of age had developed detectable liver disease after more than five years of treatment, while in the nitisinone-naive group, two transplantations were performed due to acute liver failure.

Nitisinone-treated patients in the NTBC study reported fewer liver transplantations (13%) compared with those who received dietary restriction alone (25%). In the Quebec study, more liver transplantations were performed for patients not treated with nitisinone (71%), compared with those who received nitisinone after 30 days of age (27%). In the group that received nitisinone before 30 days of age, no transplantations were needed.

Treatment of nitisinone was also related to a lower incidence of HCC; 5% in the NTBC study developed HCC compared with 8% in the historical control. In the NTBC study, all but one patient diagnosed with HCC were older than one year of age. In addition, nitisinone is associated with decreased risk of porphyric crises and fewer hospitalizations related to HT-1 complications. Shortly after the start of nitisinone, urine SA was reduced to below the reference limit (less than 1 mmol/mol creatinine). Nitisinone was associated with increased plasma levels of tyrosine and decreased levels of alpha-fetoprotein and increased platelet count.

Harms

Nitisinone was generally well tolerated. In the NTBC study, eye disorders (conjunctivitis, blepharitis, keratitis, eye pain, photophobia, and corneal opacity with symptoms of itching, burning, photophobia, corneal erosion, and corneal clouding) were the most commonly reported adverse events (AEs), with 31 events observed in 14 patients. In the Quebec study, one patient developed photophobia and corneal crystals, which disappeared within 24 hours of strict dietary restriction. Transient thrombocytopenia, neutropenia, or both were reported in 3%, 3%, and 1.5% of the study population, respectively, while there were no infections or bleeding that could be ascribed to the observed neutropenia or thrombocytopenia.

In the NTBC study, 49 serious adverse events (SAEs) were reported, including liver failure, HCC, multi-organ failure, elective liver transplantation, and thrombocytopenia. However, most of these SAEs were considered to be related to the underlying disease, not nitisinone treatment. Three cases of severe thrombocytopenia were deemed to be related to the treatment of nitisinone. No patient has been withdrawn because of AEs of nitisinone in the NTBC study. Ten deaths in the NTBC study and two in the Quebec study were reported.

Because the new drug submission filed for MDK-Nitisinone was based on literature and market experience, and all published articles used Orfadin as a drug product, there was no direct evidence of MDK-Nitisinone available to assess its clinical benefits and harms. The manufacturer performed a bioequivalence study between MDK-Nitisinone and Orfadin to link the data retrieved from the literature to MDK-Nitisinone. Results of this bioequivalence study showed that a single 10 mg capsule of MDK-Nitisinone had equivalent pharmacokinetics profiles as Orfadin in healthy volunteers.
Conclusions

Two manufacturer-submitted, single-arm, open-label studies demonstrated an association between treatment with nitisinone in combination with dietary restriction of tyrosine and phenylalanine and improved survival in patients with HT-1 as compared with a historical population that received dietary treatment alone. Greater survival benefits were observed in patients who started treatment before two months of age. Nitisinone was also associated with reduced risk of liver failure, fewer liver transplantation requirements, lower risk of HCC, fewer porphyric crises, and reduced acute complications of HT-1. Delayed nitisinone treatment (i.e., after six months of age) was associated with an increased risk of HCC and requirement of liver transplant. Eye disorders related to elevated plasma tyrosine levels with nitisinone treatment were the most commonly reported AEs. Thrombocytopenia and neutropenia may also occur with nitisinone treatment, although no serious sequelae were identified in the studies. Most of the reported SAEs were considered likely related to the underlying disease, and not nitisinone.

The included studies were limited by the open-label design and lack of a direct comparator. Moreover, no absolute or relative measures of effect with formal statistical comparisons of the outcomes were performed on nitisinone plus dietary restriction versus dietary restriction alone, and therefore there is uncertainty as to the magnitude of any benefit from nitisinone as compared with dietary restriction. However, the relatively large difference in survival probabilities (primarily if initiated in those younger than six months) and reduced morbidity as compared with a historical control suggest there is an overall clinically significant beneficial effect with nitisinone in treating patients with HT-1, although the extent to which this would be maintained over a lifetime (approximately 80 years, based on Canadian general population estimates) is associated with uncertainty.

Results of a bioequivalence study demonstrate comparable pharmacokinetic profiles for two nitisinone products, MDK-Nitisinone and Orfadin, in healthy volunteers.
Table 1: Summary of Results

<table>
<thead>
<tr>
<th>Outcome</th>
<th>The NTBC Study</th>
<th></th>
<th>The Quebec Study</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nitisinone Plus Dietary Restriction (N = 207)</td>
<td>Dietary Restriction Alone (Historical Cohort) (N = 108)</td>
<td>Nitisinone-Naive (Historical Cohort) (N = 28)</td>
<td>Late-Treatment (N = 26)</td>
</tr>
<tr>
<td>Efficacy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survival probability (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>96% (93 to 99)</td>
<td>93% (88 to 98)</td>
<td>NR</td>
<td>20/28 (71.4%) before transplant</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NR</td>
<td>24/24 (100%) before transplant</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P &lt; 0.01 for comparison of nitisinone-naive vs. nitisinone-treated groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18/20 (90%) after transplant</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(no transplant)</td>
</tr>
<tr>
<td>Start age 0 to 2 months</td>
<td>88% (65 to 100)</td>
<td>88% (52 to 100)</td>
<td>29%</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Start age 0 to 6 months</td>
<td>94% (85 to 100)</td>
<td>94% (80 to 100)</td>
<td>74%&lt;sup&gt;a&lt;/sup&gt;</td>
<td>60%&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Start age &gt; 6 months</td>
<td>97% (94 to 100)</td>
<td>93% (85 to 100)</td>
<td>96%</td>
<td>96%</td>
</tr>
<tr>
<td>Survival without liver transplant</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>84% (78 to 90)</td>
<td>78% (69 to 86)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Start age 0 to 2 months</td>
<td>88% (65 to 100)</td>
<td>88% (52 to 100)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Start age 0 to 6 months</td>
<td>85% (75 to 95)</td>
<td>82% (66 to 97)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Start age &gt; 6 months</td>
<td>83% (76 to 91)</td>
<td>76% (65 to 87)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver failure, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death related to liver failure</td>
<td>7 (3.4)</td>
<td>27 (25)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Liver transplantation, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>27 (13)</td>
<td>26 (25)</td>
<td>20 (71)</td>
<td>7 (26.9)</td>
</tr>
</tbody>
</table>
### Outcome

<table>
<thead>
<tr>
<th></th>
<th>The NTBC Study</th>
<th>The Quebec Study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nitisinone Plus Dietary Restriction (N = 207)</td>
<td>Dietary Restriction Alone (Historical Cohort) (N = 108)</td>
</tr>
<tr>
<td>HCC, n (%)</td>
<td>10 (5)</td>
<td>NR</td>
</tr>
<tr>
<td>Porphyric crises</td>
<td>1 (0.5)</td>
<td>10% of the patients died from consequences of porphyria-like crises</td>
</tr>
<tr>
<td>Biochemical variables</td>
<td>Urine SA</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>&gt; 90% of all patients normalized by 2 weeks (&lt; 1 mmol/mol creatinine)</td>
<td></td>
</tr>
<tr>
<td>Tyrosine (µmol/L)</td>
<td>140</td>
<td>387</td>
</tr>
</tbody>
</table>

### Harms

<table>
<thead>
<tr>
<th></th>
<th>SAEs, n (%)</th>
<th>WDAEs, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3 (1.4)†</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

CI = confidence interval; HCC = hepatocellular carcinoma; NR = not reported; SA = succinylacetone; SAE = serious adverse event; WDAE = withdrawal due to adverse event.

* "Late-treatment" means nitisinone treatment started after 30 days of age; "early-treatment" means nitisinone treatment started before 30 days of age.

† Data corresponded to patients two to six months of age at start of treatment.

† Forty-nine SAEs were reported, while three of them were considered to be treatment-related.

Sources: European Medicines Agency,¹ FDA medical review,² Australian public assessment report,³ Larochelle 2012,⁴ van Spronsen 1994.⁵
Introduction

Disease Prevalence and Incidence

Hereditary tyrosinemia type 1 (HT-1) is a rare, life-threatening, autosomal recessive disorder of amino acid metabolism. The deficiency of fumarylacetoacetate hydrolase (FAH), which is the last enzyme in the pathway of tyrosine catabolism, results in the accumulation of the toxic metabolites succinylacetone (SA) and succinyl acetoacetate in the FAH-deficient hepatocytes and proximal renal tubular cells, and subsequently leads to liver and kidney damage.\(^6\) HT-1 typically manifests in infancy and is characterized by elevated plasma tyrosine levels.\(^6\) For children who are not detected by newborn screening, liver dysfunction (such as bleeding abnormalities, hypoglycemia, ascites, edema, vomiting, irritability, and jaundice), is the dominant clinical manifestation. Progression of the liver disease can be chronic or acute, with rapid deterioration.\(^6,8\) Other clinical manifestations of HT-1 include renal tubular dysfunction, hypophosphatemic rickets, porphyria-like neurological crises, hypoglycemia due to islet cell hyperplasia, and cardiomyopathy. The lifetime risk of patients with HT-1 developing hepatocellular carcinoma (HCC) is high (37% in the survivors without treatment).\(^6,9,10\) Furthermore, many patients suffer from neurocognitive deficits, which may be attributed to tyrosine toxicity, phenylalanine deficiency, drug toxicity, or natural disease progression in long-term survivors.\(^11\) If untreated, survival in patients with HT-1 is less than 12 months of life. Most of these children die as a result of liver failure and severe coagulopathy.\(^12,13\)

The prevalence of HT-1 ranges from one in 12,000 to one in 100,000 individuals of Northern European descent.\(^6\) In Canada, the estimated prevalence was about one in 17,609 individuals,\(^14\) although a remarkably higher prevalence (one in 1,846 live births) was observed in the Saguenay–Lac-Saint-Jean region in Quebec, and the estimated carrier rate of a specific mutation was one in 20 to one in 25 inhabitants.\(^6,13\)

Newborn screening allows for earlier identification of the disorder and earlier intervention.\(^15\) Previous research suggests better outcomes when treatment begins at an asymptomatic stage.\(^15\) The accuracy of the newborn screening test using tandem mass spectrometry measurement of SA from dried blood spots is as high as 100%.\(^15\) Detection of SA in urine, plasma, or amniotic fluid is considered pathognomonic of tyrosinemia, as SA is not found in any other condition. Province-wide newborn screening for tyrosinemia has been practised since 1970 in Quebec,\(^16\) and the presence of SA in urine or blood is used as a confirmatory test in the Quebec newborn screening program.\(^12\) Compared with other regions, children in Quebec were identified and treated from an early stage of the disease due to the universal neonatal screening.\(^16\) All other Canadian provinces and territories, except for New Brunswick, Nova Scotia, and Prince Edward Island, have included screening for HT-1 in their newborn screening programs since 2015.\(^17\)

Standards of Therapy

Before the introduction of nitisinone, the management of HT-1 involved dietary restriction of phenylalanine and tyrosine, along with supportive treatment, until liver transplantation if possible.\(^9\) Despite a strict dietary regimen started within days of birth, progression of cirrhosis or HCC, as well as inconsistent improvement in renal tubular function, were still observed.\(^12,16\)
At present, all affected children are managed with nitisinone in combination with a tyrosine- and phenylalanine-restricted diet.

Liver transplantation remains the only definitive therapy for patients with HT-1 who do not respond to nitisinone therapy and there is progressive liver failure, or who have suspected HCC. However, liver transplantation is associated with risks of operative complications including death, graft rejection, and the challenge of organ availability.

In Quebec, provision of services to all patients is coordinated by the four university hospital centres and by a regional centre in the area with the highest prevalence of HT-1. Because of the universal neonatal screening for tyrosinemia, HT-1 patients are usually first identified as clinically asymptomatic newborns in Quebec. Information as to coordination of care in other provinces and territories was not available for this review. Screen-positive babies are usually seen within three weeks of birth, and the follow-up examinations, such as physical exams, liver function, coagulation tests, and SA levels, are conducted. Patients who have positive screen results but normal liver function are not treated but are followed closely while awaiting the results of specific tests. When evidence of liver dysfunction is observed, nitisinone and special diet are offered to the patients. The plasma-nitisinone level is used to adjust the prescription of nitisinone.

**Drug**

Nitisinone (MDK-Nitisinone) is a competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase, an enzyme upstream of FAH in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with HT-1, nitisinone prevents the accumulation of the catabolic intermediates, which can be converted to the toxic metabolites, SA and succinylacetocetate, that are responsible for liver and kidney damage. The effect of nitisinone on inhibiting catabolism of tyrosine also leads to an increase in plasma tyrosine levels. Therefore, treatment with nitisinone requires restriction of the dietary intake of tyrosine and phenylalanine to prevent tyrosine toxicity, which includes ocular symptoms, intellectual disability, developmental delay or painful hyperkeratotic plaques on the soles and palms. Plasma tyrosine levels should be maintained below 500 µmol/L to decrease the risk of ocular disorders.

MDK-Nitisinone is supplied as capsules containing 2 mg, 5 mg, 10 mg, or 20 mg of nitisinone. The 20 mg strength of MDK-Nitisinone was approved by Health Canada while the review by CADTH Common Drug Review (CDR) was ongoing. Nitisinone was provided to Canadian patients as Orfadin (reference product) since 1994 by Sobi, under the Health Canada Special Access Program, which ended in late 2016. A Notice of Compliance for MDK-Nitisinone for the treatment of adult and pediatric patients with HT-1 in combination with dietary restriction of tyrosine and phenylalanine was granted by Health Canada on September 20, 2016, based largely on bioequivalence with the reference nitisinone product, Orfadin. The recommended initial dosage of nitisinone is 1 mg/kg body weight per day, in two divided doses orally. The dose of nitisinone should be adjusted individually based on weight, biochemical, and enzyme markers. The maximum daily dose of nitisinone is 2 mg/kg.

A third nitisinone product has received Health Canada approval for the treatment of HT-1: nitisinone tablets (manufactured by Cycle Pharmaceuticals Ltd.). However, it had not been reviewed by CDR as of writing of this review.
Objectives and Methods

Objectives
To perform a systematic review of the beneficial and harmful effects of nitisinone (2 mg, 5 mg, 10 mg, and 20 mg capsules) for the treatment of patients with HT-1 in combination with dietary restriction of tyrosine and phenylalanine.

Methods
All manufacturer-provided trials considered pivotal by Health Canada were included in the systematic review. Phase III studies were selected for inclusion based on the selection criteria presented in Table 2.

Table 2: Inclusion Criteria for the Systematic Review

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>Patients with HT-1 in combination with dietary restriction of tyrosine and phenylalanine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Nitisinone</td>
</tr>
<tr>
<td>Comparators</td>
<td>Best supportive care (dietary restriction of tyrosine and phenylalanine)</td>
</tr>
<tr>
<td>Outcomes</td>
<td><strong>Key efficacy outcomes:</strong></td>
</tr>
<tr>
<td></td>
<td>Survival</td>
</tr>
<tr>
<td></td>
<td>Liver failure</td>
</tr>
<tr>
<td></td>
<td>Liver transplantation</td>
</tr>
<tr>
<td></td>
<td>Renal failure</td>
</tr>
<tr>
<td></td>
<td>HCC</td>
</tr>
<tr>
<td></td>
<td>HRQoL measured with validated scales</td>
</tr>
<tr>
<td></td>
<td><strong>Other efficacy outcomes:</strong></td>
</tr>
<tr>
<td></td>
<td>Porphyric crisis</td>
</tr>
<tr>
<td></td>
<td>Biochemical variables</td>
</tr>
<tr>
<td></td>
<td>• HT-1-related: SA, tyrosine, etc.</td>
</tr>
<tr>
<td></td>
<td>• Hepatic: PT/PTT, INR, hepatic transaminase, AFP, etc.</td>
</tr>
<tr>
<td></td>
<td>• Renal: creatinine, GFR, etc.</td>
</tr>
<tr>
<td></td>
<td>• Hematologic: erythrocyte count, thrombocyte count, neutrophil count, etc.</td>
</tr>
<tr>
<td></td>
<td>Hospitalization resulting from acute complications of HT-1</td>
</tr>
<tr>
<td></td>
<td><strong>Harms outcomes:</strong></td>
</tr>
<tr>
<td></td>
<td>AEs, SAEs, WDAEs, mortality, notable harms/harms of special interest (ocular AEs, hematological symptoms, cutaneous symptoms, tyrosine levels, etc.)</td>
</tr>
</tbody>
</table>

Study Design: Published and unpublished phase III RCTs

AFP = alpha-fetoprotein; AE = adverse event; GFR = glomerular filtration rate; HCC = hepatocellular carcinoma; HRQoL = health-related quality of life; HT-1 = hereditary tyrosinemia type 1; INR = international normalized ratio; PT = prothrombin time; PTT = partial thromboplastin time; RCT = randomized controlled trial. SA = succinylacetone; SAE = serious adverse events; WDAE = withdrawal due to adverse events.
The literature search was performed by an information specialist using a peer-reviewed search strategy.

Published literature was identified by searching the following bibliographic databases: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present; Embase (1974–) via Ovid; and PubMed. The search strategy consisted of both controlled vocabulary, such as the National Library of Medicine’s MeSH (Medical Subject Headings), and keywords. The main search concept was the drug name (Orfadin - nitisinone).

No methodological filters were applied to limit retrieval. Where possible, retrieval was limited to the human population. Retrieval was not limited by publication year or by language. Conference abstracts were excluded from the search results. See Appendix 2 for the detailed search strategies.

The initial search was completed on September 26, 2017. Regular alerts were established to update the search until the meeting of the CADTH Canadian Drug Expert Committee on January 17, 2018. Regular search updates were performed on databases that do not provide alert services.

Grey literature (literature that is not commercially published) was identified by searching relevant websites from the following sections of the Grey Matters checklist (https://www.cadth.ca/grey-matters):

- Health Technology Assessment Agencies
- Health Economics
- Clinical Practice Guidelines
- Drug and Device Regulatory Approvals
- Advisories and Warnings
- Drug Class Reviews
- Databases (free)
- Internet Search

Google and other Internet search engines were used to search for additional Web-based materials. These searches were supplemented by reviewing the bibliographies of key papers and through contacts with appropriate experts. In addition, the manufacturer of the drug was contacted for information regarding unpublished studies.

Two CDR clinical reviewers independently selected studies for inclusion in the review based on titles and abstracts, according to the predetermined protocol. Full-text articles of all citations considered potentially relevant by at least one reviewer were acquired. Reviewers independently made the final selection of studies to be included in the review, and differences were resolved through discussion. Included studies are presented in Table 3.
Results

Findings From the Literature

No studies were identified from the literature for inclusion in the systematic review (Figure 1). Two studies submitted by the manufacturer are included. The included studies are summarized in Table 3 and described in “Included Studies.”

Figure 1: Flow Diagram for Inclusion and Exclusion of Studies
Table 3: Details of Included Studies

<table>
<thead>
<tr>
<th>Study Design</th>
<th>The NTBC Study</th>
<th>The Quebec NTBC Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Locations</td>
<td>Phase II-III, single-arm, open-label, multi-centre trial</td>
<td>Single-arm, open-label trial</td>
</tr>
<tr>
<td>Enrolled (N)</td>
<td>207 patients enrolled between February 1991 and August 1997 for the main analysis; 250 patients enrolled between July 1993 and March 2000 for the complementary analysis</td>
<td>78 patients born between February 1984 and February 2004</td>
</tr>
<tr>
<td>Inclusion Criteria</td>
<td>HT-1 verified by the presence of SA in the urine or plasma</td>
<td>All known HT-1 patients in Quebec born between February 1984 and February 2004</td>
</tr>
<tr>
<td>Exclusion Criteria</td>
<td>Prior liver transplantation</td>
<td>Not specified in the published article</td>
</tr>
<tr>
<td>Intervention</td>
<td>nitisinone</td>
<td>Nitisinone late-treatment</td>
</tr>
<tr>
<td>Comparator(s)</td>
<td>Historical control, where patients received dietary treatment only</td>
<td>Nitisinone-naive patients enrolled before 1994, patients received dietary treatment and other supportive therapy</td>
</tr>
<tr>
<td>Phase</td>
<td>Run-in</td>
<td>Double-blind</td>
</tr>
<tr>
<td>Double-blind</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Follow-up</td>
<td>Patients were enrolled on an ongoing basis; all patients entered up to the point of data cut-off on August 21, 1997, were included in the main analysis</td>
<td>Data for events before 1994 were obtained from retrospective chart review, while subsequent data were recorded prospectively until liver transplant, death or date of data analysis (August 1, 2009)</td>
</tr>
<tr>
<td>Primary End Point</td>
<td>Survival</td>
<td>Hospitalization due to acute complications of HT-1</td>
</tr>
<tr>
<td></td>
<td>Survival without need for liver transplantation</td>
<td>Survival</td>
</tr>
<tr>
<td></td>
<td>Death due to liver failure</td>
<td>Liver transplantation</td>
</tr>
<tr>
<td></td>
<td>HCC</td>
<td>Neurological crises</td>
</tr>
<tr>
<td></td>
<td>Porphyrnic crises</td>
<td></td>
</tr>
<tr>
<td>Other End Points</td>
<td>Biochemical variables of liver function, kidney function, hemic system, SA, and tyrosine</td>
<td>Biochemical variables of liver function, kidney function, hemic system, SA, and tyrosine</td>
</tr>
<tr>
<td>Publications</td>
<td>Holme 1998&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Larochelle 2012&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Holme 2000&lt;sup&gt;23&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>

HCC = hepatocellular carcinoma; HT-1 = hereditary tyrosinemia 1; NA = not applicable; SA = succinylacetone; 
Note: Three additional reports were included (FDA medical review<sup>1</sup>, Australian public assessment report<sup>2</sup> and European Medicines Agency report<sup>3</sup>).  
Sources: Holme 1998<sup>22</sup>, Holme 2000<sup>23</sup> and Larochelle 2012<sup>4</sup>.
Included Studies

Description of Studies

The NTBC study was a single-arm, open-label, multinational study to investigate the efficacy and safety of nitisinone in combination with a restricted diet. The study was coordinated from Sahlgrenska University Hospital, Gothenburg, Sweden, and conducted over nine years, including a main analysis regarding 207 patients who were recruited between February 1991 and August 1997, and a complementary analysis of 250 patients who were recruited between July 1993 and March 2000. Any patients with a diagnosis of HT-1, except for those with prior liver transplantation, were eligible for inclusion. Eligible participants received oral nitisinone therapy with concomitant dietary restriction of tyrosine and phenylalanine. The study protocol required that laboratory and clinical data be reported to a common database in Gothenburg, and that urine and blood samples be sent there for measurement of critical variables. For ethical reasons the study was open-label and comparisons were made to a historical control (108 patients treated with a diet restricted in tyrosine and phenylalanine alone; the time period over which patients were recruited for the historical cohort was not specified). The NTBC study was not performed according to the current Good Clinical Practice standards, and was sponsored by industry and non-industry organizations.

The Quebec study was a single-arm, open-label study conducted in Quebec, Canada. All known HT-1 patients born between February 1984 and February 2004 were included in this study. The outcomes of children born during the first 10 years that nitisinone became available in Quebec were compared with those of patients born in the preceding decade, during which all current treatment options except nitisinone were available, including newborn screening, diet therapy, and liver transplantation. The clinical course of patients was recorded until liver transplantation, death, or August 1, 2009 (date of data analysis), whichever came first. Data for events before 1994, when nitisinone was unavailable to the Canadian patients, were obtained from retrospective chart review, while subsequent data were recorded prospectively. The Quebec study was supported by non-industry funding.

Populations

Inclusion Criteria

All patients who were diagnosed with HT-1, regardless of age of symptom presentation and treatment experience, were included in the two studies. The diagnosis of HT-1 was confirmed by the presence of elevated levels of SA in blood or urine.

In the Quebec study, three patient groups were examined: nitisinone-naive, late treatment (nitisinone started after 30 days of age), and early treatment (nitisinone started on or before 30 days of age). In the two nitisinone-experienced groups, eligible participants were required to have received nitisinone for at least two weeks and lack documented nonadherence (which was defined based on patient confirmation that they did not adhere to the nitisinone regimen and had documented, inappropriately low plasma-nitisinone levels).
**Exclusion Criteria**

In the NTBC study, patients with prior liver transplantation were excluded from the studies.

In the Quebec study, all known HT-1 patients in Quebec born between February 1984 and February 2004 were eligible. Exclusion criteria were not specified in the published articles for the Quebec study.

**Baseline Characteristics**

In the NTBC study, there were 207 patients included between February 1991 and August 1997 for the main analysis and 250 patients included between July 1993 and March 2000 for the complementary analysis. Thirty-nine Canadian patients in this study were also included in the Quebec study.

The median age of patients at enrolment was nine months with a range of zero to 21.7 months. After 1993, more patients younger than one year of age were enrolled compared with earlier years of the study. In more recent years, about 66% of the study participants were diagnosed before six months of age and more than 80% were diagnosed before two years of age. The age at start of treatment ranged from the first day of life to 21 years. However, this wide spectrum was most apparent during the first years of the study, and the number of patients with onset of nitisinone treatment before one year of age had increased over the years. There were more boys (n = 114) than girls (n = 93) included in the study.

In the Quebec study, 78 patients were enrolled: 28 never received nitisinone, 26 were in the late-treatment group, and 24 were in the early-treatment group. Demographic characteristics of these study participants were not reported.

Details of the patient characteristics are presented in Table 4.

**Table 4: Summary of Baseline Characteristics**

<table>
<thead>
<tr>
<th></th>
<th>The NTBC Study</th>
<th>The Quebec Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total, N</td>
<td>207</td>
<td>78</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>114 (55)</td>
<td>NR</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>93 (45)</td>
<td></td>
</tr>
<tr>
<td>Age at enrolment, median (range)</td>
<td>9 months (0 to 21.7 years)</td>
<td></td>
</tr>
<tr>
<td>Age 0 to 2 months at start of treatment, n (%)</td>
<td>16 (7.7)</td>
<td></td>
</tr>
<tr>
<td>Age 0 to 6 months at start of treatment, n (%)</td>
<td>80 (39)</td>
<td></td>
</tr>
<tr>
<td>Age 6 to 24 months at start of treatment, n (%)</td>
<td>62 (30)</td>
<td></td>
</tr>
<tr>
<td>Age &gt; 24 months at start of treatment, n (%)</td>
<td>65 (31)</td>
<td></td>
</tr>
</tbody>
</table>

NR = not reported.  
Sources: FDA medical review, European Medicines Agency report.

**Interventions**

In the NTBC study, nitisinone was administered orally twice daily, initially at a daily dose of 0.6 mg/kg bodyweight. Individual dose readjustments were based on the biochemical response as estimated by measurements of serum and urine SA, and other biochemical markers. From 1994, a total daily initiation dose of 1 mg/kg was recommended. For some patients (especially infants) an increased dose up to 2 mg/kg may be required. No patients received more than 3 mg/kg/day. It was recommended that the plasma tyrosine level be kept below 500 µmol/L to avoid adverse effects resulting from the nitisinone therapy.
From the beginning of the study, nitisinone was distributed from the Sahlgrenska University Hospital in Gothenburg, Sweden, to hospitals all over the world on a compassionate use basis. From late 1994 the distribution of nitisinone was gradually shifted from the hospital to Swedish Orphan Biovitrum AB (Sobi), the manufacturer of Orfadin. After 1996, Sobi was responsible for providing the drug.

In the Quebec study, dosages of nitisinone were initially fixed at 0.6 mg/kg/day or 1 mg/kg/day in two daily oral doses. For the first two years of the study, patients received a recrystallized preparation of nitisinone supplied by Lindstedt and Holme. Thereafter, they received commercially produced nitisinone. After 1999, the nitisinone dose was titrated to minimize urine SA levels. The maximum daily dose of nitisinone was 2 mg/kg. Dose adjustment was based on plasma-nitisinone level. The plasma tyrosine level was kept between 200 µmol/L and 400 µmol/L to avoid the nitisinone-related adverse effects in this study.

In both studies, the study drug was provided as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of HT-1. There was no information on other drugs and/or supportive care allowed in the studies.

Outcomes

Survival

In the NTBC study, survival was measured as overall survival, survival time without need for liver transplantation, and death due to liver failure during treatment with nitisinone. In the nitisinone-treated group, survival probability was estimated from the start of nitisinone treatment, while in the historical population survival probability was estimated from the onset of symptoms. In the Quebec study, survival data were reported as death before and after transplantation. This was one of the primary outcomes in the NTBC study.

Liver Failure

Liver failure was not specifically defined in the included studies, although presence of jaundice, elevated (not defined) aminotransferase levels, and abnormal coagulopathy were considered signs of liver failure. This outcome was presented as “death due to liver failure” and “transplantation due to liver failure” during the treatment with nitisinone in the included studies. This was one of the primary outcomes in the NTBC study.

Renal Failure

Renal failure was not defined in the included studies, although hypophosphatemia and greatly elevated alkaline phosphatase levels were considered signs of renal failure.

Liver Transplantation

In the included studies, liver transplantation was performed on patients who did not respond well to the nitisinone treatment (not defined), or those with progressive liver disease and suspected HCC. This was one of the primary outcomes in the NTBC study.

HCC

The measurement of HCC included death due to cancer, transplantation due to cancer, or cancer diagnosed during treatment with nitisinone. This was one of the primary outcomes in the NTBC study.
Porphyric Crisis

“Porphyric crisis” was measured in the NTBC study, while “neurological crisis” was reported in the Quebec study. This outcome was not defined in the included studies. Neurological crisis was defined as “painful episodes affecting extremity and/or abdominal function, accompanied by hypertension and hyponatremia” in the literature, and is considered interchangeable with porphyric crisis. This was one of the primary outcomes in the NTBC study.

Biochemical Variables

HT-1–related biochemical parameters (e.g., plasma and urine SA and plasma tyrosine), liver function (e.g., serum alanine transaminase [ALT], aspartate transaminase, prothrombin complex, and serum alpha-fetoprotein [AFP]), renal function (e.g., serum creatinine) and hemic system values (e.g., complete blood count) were collected in both studies. In the NTBC study, site physicians sent patients' blood and urine samples collected before nitisinone treatment and at regular intervals during the treatment to be analyzed at the Sahlgrenska University Hospital laboratory. The Quebec study did not explicitly state where blood and urine samples were evaluated.

Urinary SA level is a sensitive marker for the efficacy of nitisinone treatment in patients with inherently high levels of SA production. A reduction to below the detection limit means a thousand-fold reduction of the flux through the tyrosine catabolic pathway. However, in patients with barely detectable SA before start of treatment with nitisinone, disappearance of SA is no guarantee of effective treatment. There is a good correlation between urine SA level and the plasma SA level. See Appendix 4 for more details about urinary and plasma SA analysis.

Hospitalization Due to the Acute Complications of HT-1

This included hospitalizations for preventive treatment and observation during infections, and was a primary outcome in the Quebec study.

Safety

Adverse events (AEs), serious adverse events (SAEs), withdrawal due to AEs, and mortality were reported in the included studies.

Statistical Analysis

The NTBC study was an investigator-initiated study designed to include all patients with verified HT-1 who were willing to participate and who did not have a history of a previous liver transplant, with the primary objective of providing patients with compassionate access to nitisinone. No sample size or power calculations and no formal statistical analysis plan were reported.

Over the period from February 1991 to August 1997, a total of 207 patients were cumulatively enrolled into the study. All were included in the main data analysis. Kaplan–Meier analysis was used to evaluate survival, occurrences of liver transplantation, liver failure leading to death or liver transplantation, HCC, and porphyric crisis. No adjustments were made in the analyses for variation due to country or centre. All statistical tests were two-sided and no formal adjustments for multiple testing were made. The Wilcoxon signed rank test was used to compare differences in numerous outcomes pre-treatment and post-treatment (e.g., one year after initiation of nitisinone), and comparisons were within-group
The Quebec Study

In the Quebec study, three patient groups were examined, including nitisinone treatment-naïve, late-treatment and early-treatment groups. The nitisinone treatment-naïve group was used as the historical cohort.
Patient Disposition

At the time of data cut-off, 38 out of the 207 patients withdrew from the NTBC study. The main reasons for the withdrawals were death and liver transplantation (Table 5).

In the Quebec study, patient withdrawal was not specifically reported. Ten patients who were never treated with nitisinone died (eight before liver transplantation and two after liver transplantation), compared with two patients who received nitisinone treatment after 30 days of age died. Twenty nitisinone-naive patients and seven patients who received nitisinone after 30 days of age underwent liver transplantation.

Table 5: Patient Disposition

<table>
<thead>
<tr>
<th>Table 5: Patient Disposition</th>
</tr>
</thead>
<tbody>
<tr>
<td>The NTBC Study</td>
</tr>
<tr>
<td>Enrolled, N</td>
</tr>
<tr>
<td>nitisinone Early-treated (n = 24)</td>
</tr>
<tr>
<td>Discontinued, n (%)</td>
</tr>
<tr>
<td>Death during nitisinone treatment</td>
</tr>
<tr>
<td>Liver failure</td>
</tr>
<tr>
<td>HCC</td>
</tr>
<tr>
<td>Multi-organ failure</td>
</tr>
<tr>
<td>Liver transplantation</td>
</tr>
<tr>
<td>Elective</td>
</tr>
<tr>
<td>Liver failure</td>
</tr>
<tr>
<td>Suspected HCC, verified</td>
</tr>
<tr>
<td>Suspected HCC, not verified</td>
</tr>
<tr>
<td>Patients’ wish to discontinue</td>
</tr>
</tbody>
</table>

HCC = hepatocellular carcinoma; NR = not reported.

* Calculated by CADTH Common Drug Review.
Sources: European Medicines Agency report,1 Larochelle 2012.4

Exposure to Study Treatments

In the NTBC study, the median duration of treatment was 22.2 months with a minimum of 0.1 months and a maximum of 77.9 months. The total exposure in the NTBC study includes more than 1,300 patient-years.1 Of all patients enrolled in the NTBC study, 83% remain on nitisinone treatment. The usual daily dose before mid-1993 was about 0.6 mg/kg and after that time it was usually about 1 mg/kg. In the main analysis, most patients were treated with a daily nitisinone dose of 0.8 mg/kg to 1.2 mg/kg.3 In the complementary analysis, the total treatment period ranging from 0.1 months to 80.5 months.3

Of the 78 patients participating in the Quebec study, 28 never received nitisinone, 26 were treated after 30 days of age and 24 were treated before 30 days of age. A total of 1,312 patient-months without nitisinone treatment and 5,731 with nitisinone treatment were recorded.

Critical Appraisal
Internal Validity

The NTBC and Quebec studies were single-arm, open-label studies evaluating the efficacy and safety of nitisinone in patients with a rare disease, HT-1. Patients in both studies were not randomized to a comparator group, but rather compared with a historical control. These study characteristics are the main limitations of both studies. HT-1 is an uncommon disease that, prior to nitisinone, did not have another drug treatment. A study in an initial group of five Swedish HT-1 children treated with nitisinone (oral daily dose of 0.1 mg/kg to 0.6 mg/kg) over approximately eight months reported marked reductions in baseline plasma SA concentrations as well as concentrations of other toxic metabolites in the tyrosine metabolic pathway, and improved liver function. Based on these results, it was concluded that it would be unethical to include a placebo group in subsequent studies, and the NTBC study was therefore open-label and did not have a control group. Following consultation with a clinical expert involved in the review, and based on the natural history of HT-1, experience using nitisinone via Health Canada’s Special Access Programme, and the lack of a viable comparator, use of a historical control group on which to base comparisons in this case is reasonable. Patient population participating in an international survey conducted by van Spronsen et al. was used as a historical control for the NTBC study. This study was published in 1994, although the time period during which the participants were enrolled was unclear. In this study, a diagnosis of HT-1 was established with characteristic clinical features in addition to abnormal levels of metabolites or a sibling’s proven diagnosis of HT-1. Patients who were identified by neonatal screening were excluded because dietary treatment was started before clinical symptoms had developed. Although age distribution of the study participants was not reported, it suggests that these patients have a delay between the first presenting symptom and the time of diagnosis, and they were more likely to have a more severe case of the disease, compared with those in the NTBC study. There were significant clinical heterogeneities between the nitisinone-treated patient population and the historical population, and part of the survival benefits in the NTBC study could be attributed to early identification of the disease and early intervention. Information regarding the onset of symptoms, the time of diagnosis, the performance of liver transplantation, the survival rate, the suspicion of possible development of a tumour, existence of proven HCC, and the cause of death was collected. The Kaplan–Meier method was used for the estimation of survival probabilities. It is unknown if propensity scores were used to help minimize differences between cohorts in comparison between the two populations. No other adjustments were performed to eliminate the impact of potential confounders and/or effect modifiers. In the two nitisinone-experienced groups in the Quebec study, eligible participants were required to have received nitisinone for at least two weeks and lack documented nonadherence (which was defined as patient confirmation that they did not adhere to the nitisinone regimen and had documented inappropriately low plasma-nitisinone levels). Bias could be introduced when analyzing patients who were not adherent or had low levels of plasma-nitisinone after two weeks of treatment, if they were excluded from the study or classified as “nitisinone-naïve.”

The diagnosis of HT-1 was confirmed by measuring urine or blood SA when a positive newborn screening result was found. This method is recommended by published literature and clinical practitioners, therefore a misdiagnosis was unlikely in the study population. Furthermore, the study protocol required that laboratory and clinical data be reported to a common database in Gothenburg, Sweden, and that urine and blood samples be sent there for measurement of critical variables. As a result, the risk of potential review bias was likely reduced.
There was a change in the study drug formulation during the NTBC study, from a lactose formulation to pregelatinized starch formulation. The bioequivalence between the two formulations has been demonstrated in healthy adult volunteers and patients with HT-1,3 and therefore this change is unlikely to affect the validity of the results in a meaningful way. Also the initial dosage of nitisinone increased from 0.6 mg/kg/day during the first years of the study to 1 mg/kg/day after 1993 because the investigators did not think the original dose was sufficiently effective due to persistence of high levels of metabolites. The 207 patients enrolled between February 1991 and August 1997 in the main analysis received the lower doses and 250 patients enrolled between July 1993 and March 2000 received the currently recommended dose of 1 mg/kg. The maximum daily dose was 3 mg/kg. It is estimated that the analyses shared about 150 patients enrolled in a common overlapping time period.3 As a result of the substantial number of shared patients, the results of the two analyses tended to be similar. On the other hand, compared with the lower dose, the dose of 1 mg/kg may result in more clinical benefits, as well as more drug-related adverse effects.

Formal statistical comparisons were complicated by the essentially observational nature of the included studies and use of a historical control. Because of the variation in study design, there were significant heterogeneities between the cohorts, for instance the inclusion criteria of the included studies, age of onset of symptoms, previous treatment, and change in practice pattern such as improved newborn screening and earlier intervention. In the NTBC study, bias could also be introduced as the initiation of the survival analysis in the nitisinone-treated group (survival probability was estimated from the start of nitisinone treatment) was different from the analysis in the historical population (survival probability was estimated from the onset of symptoms and therefore would have better survival outcomes). These are potential confounders for study drug evaluation, but they were not adjusted for during the data analyses. Subgroup analyses would be challenging in studies with small sample size. It is unclear how this would affect the comparisons between the study participants in the NTBC study and the historical population.

In the NTBC study, patients were enrolled on an ongoing basis and all patients entered up to the point of data cut-off on August 21, 1997, were included in the main analysis. Therefore, as expected with this type of cohort, each patient had been on treatment for a different period of time, and the number of patients who were available for inclusion in survival analysis after two and four years of treatment was 95 and 35, respectively. In the absence a statistical power analysis, there is uncertainty about how robust the comparisons between cohorts are. This is somewhat mitigated by the large differences in the survival probabilities between the nitisinone-treated cohort and the non-treated historical cohort. Nevertheless, the lack of precise estimates of treatment effects of nitisinone plus dietary restriction relative to dietary restriction alone are important limitations leading to uncertainty in the data.

The incomplete reporting of results in the Quebec study (lack of description on demographic characteristics, no details reported for some of the biochemical parameters) also limits the ability to interpret the clinical significance of the efficacy results.

External Validity

The studies attempted to include any patient with confirmed HT-1, irrespective of age and clinical condition. The only exclusion criterion in the NTBC study was previous liver transplantation; no exclusion criteria were specified for the Quebec study. Although both studies provided limited descriptions of patient characteristics, discussion with the clinical expert involved in the review suggested that the populations were likely representative of
the population in Canada. For patients who started nitisinone after six months of age, and/or with asymptomatic disease, the treatment benefit remains unclear or highly uncertain. Given a precise estimate of treatment effect was unavailable, it is difficult to assess the external validity of the findings.

In addition, the Quebec study would be valuable in assessing the drug in a Canadian context.

Some of the important clinical outcomes identified by the patient groups were not measured, such as health-related quality of life of the patients or caregivers, developmental delay, or cognitive deficits.

Nitisinone should be administered along with a low-tyrosine/phenylalanine diet to patients with HT-1. There is little research regarding adherence to medication or diet in HT-1, although previous study indicates that adherence may be suboptimal, particularly with regard to dietary restrictions. Patient adherence to recommended treatment regimens was not reported in the included studies, and it is therefore not possible to explore the relationship between adherence and treatment effect on death, liver failure, development of HCC, and other clinically important outcomes.

Furthermore, neither of the two studies evaluated the clinical effectiveness and safety of MDK-Nitisinone in particular. The available evidence was from clinical trials of Orfadin. The pharmacokinetic parameters of MDK-Nitisinone were compared with that of Orfadin in a bioequivalence study in healthy volunteers. One single dose was administered. Therefore, the long-term effect of MDK-Nitisinone in comparison with Orfadin in patients with HT-1 is unclear.

Efficacy

Only those efficacy outcomes identified in the review protocol are reported below (Table 2).

Survival

Overall Survival

Higher survival probability was observed in nitisinone-treated patients in the NTBC study compared with those who received dietary restriction only in the historical control, for whom liver failure and/or recurrent bleeding were the primary causes of death in this population prior to the introduction of nitisinone, and survival did not extend past 12 years of age for any patients (Table 6). The two-year and four-year overall probabilities of survival for patients who initiated nitisinone at any age were 96% (N = 95) and 93% (N = 35), respectively. In addition, survival probability was explored in subgroups based on the age of starting nitisinone treatment. For patients who started before two months of age, their two-year and four-year overall survival rates were 88% and 88%, respectively; for those who started before six months of age, the two-year and four-year overall survival rates were 94% and 94%, respectively; for those who started after six months of age, the two-year and four-year overall survival rates were 97% and 93%, respectively. It is unclear whether the initiation of nitisinone therapy was indicated by the occurrence of any symptoms in the NTBC study. In the historical population, the two-year survival rates were 29%, 74%, and 96% for patients in whom symptoms developed before two months, from two months to six months, and after six months of age, respectively. The four-year survival rates were similar to the two-year
survival rates in the historical population for all three subgroups of patients.\textsuperscript{2} Results of the complementary analysis were similar to those in the main analysis; the overall survival for patients who initiated nitisinone at any age was 93% at two years, four years and six years (Appendix 3).

In the Quebec study, eight patients in the treatment-naive group died before liver transplantation, compared with no patients in either nitisinone-treated group (\textit{P} value for between-group difference < 0.01). After liver transplantation, two in the treatment-naive group and two in the late-treatment group died (the between-group difference was not statistically significant; \textit{P} value not reported).

\textit{Survival Without Liver Transplantation}

In the NTBC study, the two-year and four-year survival probabilities in patients who did not have liver transplantations were 84% and 78%, respectively.

\textit{Liver Failure-Related Death}

In the NTBC study, the four-year cumulative probability of death or transplantation due to liver failure was 13%.\textsuperscript{2} In the historical population, approximately 32% of the patients died due to liver failure or recurrent bleeding, or were transplanted due to liver failure.\textsuperscript{2,24}

Results of survival probability from the complementary analysis in which 250 participants were included are presented in Appendix 4.

\begin{table}
\centering
\\textbf{Table 6: Survival Probability}\\
\begin{tabular}{|l|c|c|c|c|}
\hline
\textbf{Study population} & \textbf{The NTBC Study} & \textbf{The Quebec NTBC Study} \\
\textbf{} & \textbf{Patients treated with nitisinone + dietary restriction\textsuperscript{a}} & \textbf{Dietary restriction alone (historical control)\textsuperscript{b}} & \textbf{Nitisinone-naive (historical control)} & \textbf{Late-treatment} & \textbf{Early-treatment} \\
\hline
\textbf{N} & 207 & 108 & \textbf{N} & 78: nitisinone-naive 28 late-treatment 26 early-treatment 24 \\
\hline
\textbf{Survival (95\% CI)} & & & & & \\
\hline
\textbf{Overall} & 2 year & 4 year & 2 year & 4 year & \\
96\% (93 to 99) & 93\% (88 to 98) & NR & 20/28 pts (71.4\%) before transplant & 26/26 pts (100\%) before transplant & 24/24 pts (100\%) before transplant \\
\textit{P} < 0.01 for comparisons between nitisinone-naive and nitisinone-treated groups \\
18/20 pts (90\%) after transplant & 5/7 pts (72\%) after transplant & No transplant & & & \\
\textit{P} > 0.05 for comparison between nitisinone-naive and late-treatment group \\
\hline
\textbf{Start age} & 88\% (65 to 100) & 88\% (52 to 100) & 29\% & 29\% & \\
0 to 2 months & & & & NR & \\
\textit{Start age} & 94\% (85 to 100) & 94\% (80 to 100) & 74\%c & 60\%c & \\
0 to 6 months & & & & & \\
\textit{Start age} & 97\% (94 to 100) & 93\% (85 to 100) & 96\% & 96\% & \\
> 6 months & & & & & \\
\hline
\end{tabular}
\end{table}
**The NTBC Study** | **The Quebec NTBC Study**
---|---
**Survival without liver transplant** |  
Overall & 84% (78 to 90) & 78% (69 to 86) & NR & NR  
Start age 0 to 2 months & 88% (65 to 100) & 88% (52 to 100)  
Start age 0 to 6 months & 85% (75 to 95) & 82% (66 to 97)  
Start age > 6 months & 83% (76 to 91) & 76% (65 to 87)  

CI = confidence interval; NR = not reported; pt = patient.

* Survival probability of nitisinone + dietary restriction was estimated from the start of nitisinone treatment.

+ Survival probability of dietary restriction alone was estimated from the onset of symptoms.

+ Data corresponded to patients two to six months of age at start of treatment.

Sources: European Medicines Agency,1 FDA medical review,2 van Spronsen 1994.5

**Liver Failure**

In the NTBC study, a total of 6.8% of patients (14 of 207) died or were transplanted due to liver failure in the main analysis: seven patients (3.4%) died of liver failure and seven transplantations (3.4%) were performed due to liver failure (Table 7). For patients whose treatment started before six months of age, seven of 80 (9%) died of liver failure or were transplanted due to liver failure.1 In the historical control, 25% of patients (27 of 108) died of liver failure and 6.4% (six of 108) underwent transplantation due to liver failure. For patients with symptom onset before six months, 35 of 83 (42%) died of liver failure or recurrent bleeding with or without liver failure (data were only reported with recurrent bleeding).1

In the Quebec study, no early-treated patients had developed detectable liver disease after more than five years of treatment, while in the treatment-naive group, two transplantations were performed due to acute liver failure. No data were presented for the late-treated group.

**Table 7: Liver Failure (n, %)**

<table>
<thead>
<tr>
<th>Study population</th>
<th>The NTBC Study</th>
<th>The Quebec Study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nitisinone + dietary restriction</td>
<td>Dietary restriction alone (historical control)</td>
</tr>
<tr>
<td>Death due to liver failure</td>
<td>N = 207</td>
<td>N = 108</td>
</tr>
<tr>
<td>Transplant for liver failure</td>
<td>7 (3.4)</td>
<td>27 (25)</td>
</tr>
</tbody>
</table>

NR = not reported.

- van Spronsen et al. 1994.

Sources: European Medicines Agency report,1 FDA medical review,2 Australian public assessment report,3 Larochelle 2012,4 van Spronsen 1994.24
Liver Transplantation

In the NTBC study, a total of 27 (13%) liver transplantations were performed: 20 for liver failure, HCC, or suspected HCC, and seven for elective transplantations (Table 8). In the historical control, 26 patients (25%) underwent liver transplantation for end-stage liver disease, porphyria symptoms, verified or presumed HCC, or elective surgery. In the Quebec study, more liver transplantations were performed for patients with restricted diet alone (71%) compared with those who received nitisinone after 30 days of age. In the group that received nitisinone before 30 days of age, no patients required liver transplantation during the study.

Table 8: Liver Transplantation (n, %)

<table>
<thead>
<tr>
<th>Study population</th>
<th>The NTBC Study</th>
<th>The Quebec NTBC Study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nitisinone + dietary restriction</td>
<td>Dietary restriction alone (historical control)</td>
</tr>
<tr>
<td>Overall</td>
<td>N = 207</td>
<td>N = 108</td>
</tr>
<tr>
<td>Transplant for liver failure</td>
<td>27 (13)</td>
<td>26 (25)</td>
</tr>
<tr>
<td>Transplant for HCC</td>
<td>7 (3)</td>
<td>7 (6%) for end-stage liver disease; 5 (5%) for combination of end-stage liver disease and porphyria symptoms; 4 (4%) for HCC; 6 (6%) for suspected HCC which was not verified at time of transplant; 4 (4%) elective transplant</td>
</tr>
<tr>
<td>Transplant for suspected HCC, not verified</td>
<td>6 (3)</td>
<td>0</td>
</tr>
<tr>
<td>Elective transplant</td>
<td>7 (3)</td>
<td>0</td>
</tr>
</tbody>
</table>

HCC = hepatocellular carcinoma.

* van Spronsen et al. 1994.


Hepatocellular Carcinoma

A total of 10 patients (5%) in the NTBC study developed HCC, which occurred at 0.5, 4, 9, 10, 10, 12, 18, 30, 32, and 42 months after starting therapy with nitisinone. All patients were older than one year of age except one.

In the NTBC study, the cumulative probability of death due to HCC, transplantation due to HCC, or diagnosis of HCC for all patients who started nitisinone treatment after two years of age was 8%, 12%, and 27% at one, two, and four years, respectively; for patients who started nitisinone treatment before two years of age, this cumulative probability was 1% at all three time points. In the historical control, HCC developed in 8% of the patients.

In the Quebec study, HCC was found at transplantation in one patient in the late-treatment group (3.8%).

Health-Related Quality of Life

This outcome was not assessed in the included studies.
Porphyric Crisis

In the NTBC study, no cases of fatal porphyric crises were observed. One patient developed a mild porphyric crisis during the study.\textsuperscript{2} In the historical population, 10% died from consequences of porphyria-like crises.\textsuperscript{24}

In the Quebec study, patients in the nitisinone-naive group spent 71 months in hospital for neurologic crises, compared with 17 months in the case of the late-treatment group and zero months in the case of the early-treatment group.\textsuperscript{4} The numbers of patients involved in these events were not reported.

Biochemical Variables

The results of biochemical variables were not reported in sufficient details in the Quebec study. Results of the NTBC study are provided in Table 9.

*Succinylacetone*

In the NTBC study, before treatment, urine SA varied from barely detectable to $> 1,000$ mmol/mol creatinine. In the main analysis, urine SA was reduced to below the reference limit (less than 1 mmol/mol creatinine) in 0.3 months after start of the nitisinone therapy. Plasma SA also decreased to below the reference limit (less than 0.1 µmol/L), with a median time to normalization of 3.9 months. In the complementary analysis, similar findings were reported.

*Tyrosine*

After one year of treatment, the plasma level of tyrosine increased from 140 µmol/L to 387 µmol/L.

*Liver Function*

After one year of treatment, the median serum ALT level increased by 30%, but the level of aspartate transaminase was lower than the pre-treatment values. At the start of therapy, the median of international normalized ratio was 1.675; this outcome decreased to 1.15 (reference range 0.80 to 1.20) after one month of treatment. The median of AFP level decreased from 471 mcg/L before treatment to 3 mcg/L after one year of treatment.

*Renal Function*

The serum creatinine was within the normal range at pre-treatment and there was no significant change observed during the treatment of nitisinone. The median level of urine amino acids decreased from 7,535 mmol/mol creatinine before treatment to 1,372 mmol/mol creatinine after one year of treatment.

*Hematologic*

The neutrophil counts were within the normal range before the treatment. There was no significant change observed during the study. The median pre-treatment platelet count increased from 133,000/µL to 228,000/µL after one year of treatment.
### Table 9: Laboratory Variables

<table>
<thead>
<tr>
<th>Study population</th>
<th>The NTBC Study</th>
<th>The Quebec NTBC Study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre–nitisinone treatment</td>
<td>1-year visit</td>
</tr>
<tr>
<td><strong>HT-1 specific biochemical variables</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine SA</td>
<td>&gt; 90% of all patients normalized by 2 weeks (&lt; 1 mmol/mol creatinine)</td>
<td>Urine SA levels decreased 7.3-fold 12 hours following the first dose of nitisinone; after 1 week of nitisinone therapy, urine SA levels were not significantly different from those ≥ 3 months later. Data were presented graphically.</td>
</tr>
<tr>
<td>Plasma SA</td>
<td>&gt; 80% of patients by 6 months (&lt; 0.1 µmol/L)</td>
<td>NR</td>
</tr>
<tr>
<td>Median tyrosine (µmol/L)</td>
<td>140 (n = 193)</td>
<td>387 (n = 114)</td>
</tr>
<tr>
<td><strong>Liver function</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median ALT (U/L)</td>
<td>56</td>
<td>73</td>
</tr>
<tr>
<td>Median AST (U/L)</td>
<td>90</td>
<td>77</td>
</tr>
<tr>
<td>Median INR</td>
<td>1.675 in 60 patients</td>
<td>1.15 in 51 patients after 1 month treatment</td>
</tr>
<tr>
<td>Median AFP (mcg/L)</td>
<td>471</td>
<td>3</td>
</tr>
<tr>
<td><strong>Renal function</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum creatinine</td>
<td>Within the normal range</td>
<td>No significant changes were observed</td>
</tr>
<tr>
<td>Urine amino acids (mmol/mol creatinine)</td>
<td>7,535 (this outcome was followed only in patients with elevated levels at pre-treatment, n = 13)</td>
<td>1,372</td>
</tr>
<tr>
<td><strong>Hematologic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophil counts</td>
<td>Within the normal range</td>
<td>No significant changes were observed</td>
</tr>
<tr>
<td>Median platelet counts/µL</td>
<td>133,000 (n = 127)</td>
<td>228,000 (n = 53)</td>
</tr>
</tbody>
</table>

AFP = alpha-fetoprotein; ALT = alanine transaminase; AST = aspartate transaminase; HT-1 = hereditary tyrosinemia type 1; INR = international normalized ratio; NR = not reported; SA = succinylacetone.

Sources: FDA medical review, Larochelle 2012.4
Hospitalization Resulting From Acute Complications of HT-1

In the Quebec study, patients in the nitisinone-naive group and those in the pre-nitisinone period of the later-treatment group spent a total of 56 of 784 months in the hospital. No patients developed an acute HT-1-related complication while treated with nitisinone. 

Harms

Only those harms identified in the review protocol are reported below (Table 2).

Adverse Events

The occurrence of overall AEs in the NTBC main analysis was not reported. In the complementary analysis of the NTBC study, 51.2% (128 of 250) of patients experienced at least one AE. 

Eye disorders (conjunctivitis, blepharitis, keratitis, eye pain, photophobia, and corneal opacity with symptoms of itching, burning, photophobia, corneal erosion, and corneal clouding) were the most commonly reported AEs, with 31 events observed in 14 patients.

Transient thrombocytopenia, neutropenia, or both were reported in 3%, 3%, and 1.5% of the study population, respectively, while there were no infections or bleeding that could be ascribed to the observed neutropenia or thrombocytopenia. Details of the harm data in the NTBC study are presented in Table 10.

In the Quebec study, one patient developed photophobia and corneal crystals, which disappeared within 24 hours of strict dietary restriction.

Serious Adverse Events

In the main analysis of the NTBC study, 49 SAEs were reported, including liver failure (14), HCC (10 verified, six not verified), multi-organ failure (one), elective liver transplantation (seven), and thrombocytopenia (three). The three cases of thrombocytopenia, which were all transient, were the only SAEs considered to have a possible relationship to nitisinone, whereas the other aforementioned events were reported by the investigators as likely related to the underlying disease and not nitisinone treatment.

The Quebec study did not report data on SAEs.

Withdrawal Due to Adverse Events

In the main analysis of the NTBC study, no patient has been withdrawn because of AEs associated with the drug. No data were reported for withdrawals due to AEs in the Quebec study.

Mortality

During the treatment with nitisinone in the NTBC study, there were 10 deaths reported in the main analysis of the NTBC study, due to liver failure (seven patients), HCC (two), and multi-organ failure (one). In the complementary analysis, 15 deaths (6.0%) in 250 patients treated with nitisinone were reported, with eight due to liver failure, two to HCC, two to multi-organ failure, one to gastrointestinal bleeding, one to complications of prematurity and one to an unspecified reason.
In the Quebec study, 10 patients in the never-treated group died, while two patients in the late-treatment group died during the study.\(^4\)

**Notable Harms**

In the NTBC study, the tyrosine concentration was described as “tends to be higher in patients with eye symptoms.” No details were reported. Several patients with occasional tyrosine levels above 1,000 µmol/L had not experienced any eye symptoms. The median tyrosine concentration increased from 140 µmol/L to 387 µmol/L after one year of treatment with nitisinone.

In the Quebec study, all 12 episodes of asymptomatic elevations of ALT levels ≥ 60 IU/L spontaneously resolved without changes in dose of the study drug.

**Table 10: Harms**

<table>
<thead>
<tr>
<th></th>
<th>The NTBC Study (N = 207)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AEs(^a)</strong></td>
<td></td>
</tr>
<tr>
<td>Subjects with &gt; 0 AEs, n (%)</td>
<td>NR</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>6 (3)</td>
</tr>
<tr>
<td>Dermatitis exfoliativa</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>3 (1.4)</td>
</tr>
<tr>
<td>Granulocytopenia</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Leucopenia</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Blepharitis</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Corneal opacity</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Eye pain</td>
<td>3 (1.2)</td>
</tr>
<tr>
<td>Keratitis</td>
<td>5 (2)</td>
</tr>
<tr>
<td>Photophobia</td>
<td>4 (2)</td>
</tr>
<tr>
<td><strong>SAEs, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>severe thrombocytopenia</td>
<td>3 (1.4)(^b)</td>
</tr>
<tr>
<td><strong>WDAEs, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td><strong>Deaths, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 (4.83):</td>
</tr>
<tr>
<td></td>
<td>liver failure 7 (3.38)</td>
</tr>
<tr>
<td></td>
<td>HCC 2 (0.97)</td>
</tr>
<tr>
<td></td>
<td>Multi-organ failure 1 (0.48)</td>
</tr>
</tbody>
</table>

AE = adverse event; HCC = hepatocellular carcinoma; NR = not reported; SAE = serious adverse event; WDAE = withdrawal due to adverse event.

\(^a\) May be causally related to treatment with nitisinone.

\(^b\) Forty-nine SAEs were reported, while three of them were considered to be treatment-related.

Source: European Medicines Agency report.\(^1\)
Discussion

Summary of Available Evidence

Two manufacturer-submitted, single-arm, open-label studies were included in this review to provide evidence for the clinical efficacy and safety of nitisinone in patients with HT-1. The NTBC study (N = 207 in the main analysis) enrolled patients from 25 countries, including Canada (39 patients), between February 1991 and August 1997. Patients were diagnosed by the presence of SA in the urine or plasma. In the main analysis of the NTBC study, 207 patients received nitisinone at a starting dosage of 0.6 mg/kg/day to 1 mg/kg/day; a complementary analysis was performed on 250 patients who received nitisinone at the currently recommended starting dosage of 1 mg/kg/day. The NTBC study has been conducted over nine years. Results of the NTBC study were compared with a historical population that received the dietary treatment alone. The study protocol required that laboratory and clinical data be reported to a common database in Gothenburg, Sweden, and that urine and blood samples be sent there for measurement of critical variables. A patient group participating in an international survey was used as the historical control for the NTBC study. All these patients received dietary treatment alone. The study of the historical control was published in 1994, although the time period from which the study participants were enrolled was not specified. In the Quebec study (N = 78), the outcomes of children born during the first 10 years after nitisinone became available in Quebec were compared with those of patients born in the preceding decade, during which all current treatment options except nitisinone were available. Nitisinone was initially administered at 0.6 mg/kg/day or 1 mg/kg/day, and it was increased to 1 mg/kg/day after the first few years of the study. Nitisinone-treated patients were compared with those who never received nitisinone therapy, in the same centre. Survival probability, occurrence of liver failure, requirement of liver transplantation, development of HCC, porphyric crises, hospitalization due to acute HT-1–related complications, and biochemical variables related to HT-1 were examined.

The main limitation was that both studies were single-arm, and the clinical benefits and harms of nitisinone in combination with dietary restriction of tyrosine and phenylalanine were examined by comparing with a historical control. No formal statistical test was performed on the outcomes between treatment and control. No precise estimates of treatment effects of dietary restriction plus nitisinone relative to dietary restriction alone were produced. In addition, significant heterogeneity was observed between patients treated with nitisinone in combination with dietary restriction and the historical control (dietary restriction alone). Therefore, this renders it difficult to assess the benefit of nitisinone in combination with dietary restriction, although a protective effect on a series of pre-specified clinically relevant long-term outcomes, such as survival, and liver and renal functions, are highly likely. However, given the nature of such a severe, life-threatening, and rare disease, such a single-arm trial design seems acceptable.

Interpretation of Results

Efficacy

In general, survival probability was higher in patients treated with nitisinone. In the NTBC study, the two-year and four-year overall survival rates for patients who initiated nitisinone
at any age were 96% and 93%, respectively. In addition, survival probability was explored in subgroups based on the age of starting nitisinone treatment. For patients who started before two months of age, their two-year and four-year overall survival rates were 88% and 88%, respectively; for those who started before six months of age, the two-year and four-year overall survival rates were 94% and 94%, respectively; for those who started after six months of age, the two-year and four-year overall survival rates were 97% and 93%, respectively. Results of the complementary analysis were similar to those in the main analysis: the overall survival for patients who initiated nitisinone at any age was 93% at two years, four years and six years. In the historical population that received dietary treatment alone, the two-year survival rates were 29%, 74%, and 96% for patients in whom symptoms developed before two months, from two months to six months, and after six months of age, respectively. The four-year survival was similar to the two-year survival in the historical population, for all three subgroups of patients. The results suggest that nitisinone in combination with dietary restriction has a benefit on survival compared with dietary restriction alone if started before two months of age. The results of the NTBC study were supported by the Quebec study, where higher mortality rates were observed in patients who never received nitisinone treatment compared with those treated with nitisinone.

Patients treated with nitisinone had a lower risk of death or transplantation due to liver failure. In the NTBC study main analysis, in total 14 patients (6.8%) died or were transplanted due to liver failure: seven (3.4%) died and seven (3.4%) underwent transplantations. For patients whose treatment started before six months of age, 9% (seven of 80 patients) died of liver failure or were transplanted due to liver failure. In the historical control, approximately 30% of patients died or were transplanted due to liver failure: 27 (25%) died and six (6.4%) underwent transplantation. According to the European Medicines Agency report, for patients in the historical cohort with symptom onset before six months, 42% died of liver failure or recurrent bleeding with or without liver failure (data were only reported with recurrent bleeding). The results imply that treatment with nitisinone reduces the risk of fatal liver disease in patients presenting with the acute form of HT-1 before six months of age. In the Quebec study, no early-treated patients had developed detectable liver disease after more than five years of treatment, while in the nitisinone-naive group, two liver transplantations were performed due to acute liver failure.

Nitisinone-treated patients required fewer liver transplantations compared with those who received dietary restriction alone. The NTBC study reported that liver transplantation was performed in 13% of the study participants, while in the historical control, 25% underwent the procedure. In the Quebec study, more liver transplantations were performed for patients not treated with nitisinone, compared with those who received nitisinone after 30 days of age. In the group that received nitisinone before 30 days of age, no transplantations were needed.

Treatment with nitisinone was also related to lower incidence of HCC: 5% of the patients in the NTBC study developed HCC compared with 8% in the historical control. In the NTBC study, all but one patient diagnosed with HCC were older than one year of age. Early detection of HCC is a priority for the clinical management of HT-1. Although the results suggest a benefit with nitisinone treatment reducing the occurrence of HCC, the results still indicate that non-transplanted HT-1 patients, even if they have been treated by nitisinone, are still considered to be at risk and need to be followed for the development of HCC.

In addition, the data suggest that nitisinone is associated with a decreased risk of porphyric crises and fewer hospitalizations related to HT-1 complications.
Both studies reviewed were approximately 10 years in duration. However, the extent to which the potential survival and morbidity benefits with nitisinone over dietary restriction alone would be maintained beyond the duration of the studies is uncertain.

Before treatment with nitisinone, urine SA varied from barely detectable to greater than 1,000 mmol/mol creatinine. Shortly after the start of nitisinone, urine SA was reduced to below the reference limit for the laboratory test (< 1 mmol/mol creatinine). According to previous research, SA levels must be near or below the detection limit of standard assays to demonstrate an optimal treatment effect, although no formal minimal clinically important difference has been established for SA concentrations in the urine or blood (Appendix 4).

Nitisinone was associated with increased plasma levels of tyrosine and decreased AFP levels. There was no significant change in the serum creatinine levels but the level of urine amino acids decreased after one year of treatment. The platelet count increased as well after one year of treatment.

Harms

In the NTBC study, eye disorders (conjunctivitis, blepharitis, keratitis, eye pain, photophobia, and corneal opacity with symptoms of itching, burning, photophobia, corneal erosion, and corneal clouding) were the most commonly reported AEs, with 31 events observed in 14 patients. In the Quebec study, one patient developed photophobia and corneal crystals, which disappeared within 24 hours of strict dietary restriction. Transient thrombocytopenia, neutropenia, or both were reported in 3%, 3%, and 1.5% of the study population, respectively, while there were no infections or bleeding that could be ascribed to the observed neutropenia or thrombocytopenia.

In the NTBC study, 49 SAEs were reported, but most were considered by the investigators to be related to the underlying disease, and not nitisinone treatment. Of the 49 SAEs, three cases of severe thrombocytopenia were deemed to be related to the treatment of nitisinone. No patient has been withdrawn because of AEs associated with nitisinone in the NTBC study. Ten deaths in the NTBC study and two patients in the Quebec study were reported. Due to the lack of information on treatment adherence, it is not possible to examine the relationship between treatment effect (on survival or other clinically important outcomes) and treatment adherence.

Other Considerations

Because the new drug submission filed for MDK-Nitisinone was based on literature and market experience, and all published articles used Orfadin as a drug product, there was no direct evidence of MDK-Nitisinone available to assess its clinical benefits and harms. The manufacturer performed a bioequivalence study of MDK-Nitisinone and Orfadin to link the data retrieved from the literature to MDK-Nitisinone. Results of this bioequivalence study showed that a single 10 mg capsule of MDK-Nitisinone had equivalent pharmacokinetic profiles as Orfadin in healthy volunteers, and no safety signals emerged from this study. Details of this study are presented in Appendix 5.

Potential Place in Therapy

---

a This information is based on information provided in draft form by the clinical expert consulted by CDR reviewers for the purpose of this review.
Although HT-1 is a pan-ethnic disease worldwide, in Canada the highest incidence is found in French-Canadian descendants from the Saguenay–Lac-St-Jean region in Quebec. In this population, HT-1 is a severe disease that presents in early infancy with any combination of chronic hepatopathy, failure to thrive, renal insufficiency, and neurological disease with pain crises. The natural course of the disease is degenerative, leading to liver failure, hepatocellular carcinoma, hypertension, renal failure, and hypophosphatemic rickets. Patients often die in childhood, with 60% mortality by one year of age if symptoms present before two months of age. There is no cure. Early attempts at treatment included diet therapy with tyrosine and phenylalanine restriction, which can counter some of the effects of kidney disease and temporarily mitigate some of the neurological symptoms, but individuals can still develop liver cancer and have reduced life expectancy later in childhood. Liver failure or cancer (HCC) has been treated with liver transplant, but this is not completely effective in cases with advanced symptoms at the time of transplant. Patients require immunosuppression, and deaths can occur after liver transplant from surgical complications, organ rejection, severe underlying disease, or undetected metastatic disease. Therefore, there is a significant unmet medical need for an agent that can effectively reduce the complications of the disease, improve quality of life, reduce the risk of developing liver disease and cancer, and improve life expectancy.

Nitisinone is typically started at a dosage of 1 mg/kg/day, which in practice is often sufficient to improve clinical symptoms, but higher dosages up to 2 mg/kg/day may be needed to eliminate detection of SA in the urine in acute crises. Adult patients or those with a high body mass index may be dosed at 35 mg/m² body surface area per day. A typical target range of plasma nitisinone is 30 µmol/L to 50 µmol/L.

Nitisinone can increase tyrosine levels in the blood, which can lead to corneal opacities and hyperkeratotic lesions of the palms and soles. High tyrosine levels can also lead to neurological symptoms. The increased tyrosine levels can be treated with a tyrosine-restricted diet. Plasma tyrosine levels should be kept below 500 µmol/L. Nitisinone can lead to eye symptoms such as itching, burning, or photophobia, and corneal opacification can develop. Developmental delay has been detected in patients using nitisinone, although it is not clear if this is because they are surviving and it is the natural history of the disease, dietary restriction, or the elevated tyrosine levels that result with nitisinone use. Rarer hematologic side effects include leucopenia and thrombocytopenia. Gastrointestinal upset has also been reported.

It seems clear that pre-symptomatic diagnosis and treatment produces the best outcome which can be accomplished by newborn screening, which is performed in Quebec, but not in all provinces.

It is possible not all patients respond to nitisinone, especially when treatment is delayed, and even in those with improvement in hepatocellular disease and decline in serum AFP levels can later develop HCC, so they should continue to be monitored. Based on the reviewed data, it appears very rare to have HCC develop with early onset of therapy within the first two months of life.

Monitoring of patients should be performed in centres with clinicians familiar with the management of HT-1. Nitisinone treatment should not be interrupted and can be continued even if a patient receives a liver transplant. Most centres monitor SA levels, plasma amino acids, liver enzymes, alkaline phosphatase, complete blood count, AFP, and neurocognitive assessments, and have regular tumour surveillance imaging.
No proven clinical benefit has been published for the use of nitisinone in alkaptonuria, and nitisinone is not indicated for other types of tyrosinemia.

Conclusions

Two manufacturer-submitted, single-arm, open-label studies demonstrated an association between treatment with nitisinone in combination of dietary restriction of tyrosine and phenylalanine and improved survival in patients with HT-1 as compared with a historical population that received dietary treatment alone. Greater survival benefits were observed in patients who started treatment before two months of age. Nitisinone was also associated with reduced risk of liver failure, fewer liver transplantation requirements, lower risk of HCC, fewer porphyric crises and reduced acute complications of HT-1. Delayed nitisinone treatment (i.e., before six months of age) was associated with an increased risk of HCC and requirement of liver transplant. Eye disorders related to elevated plasma tyrosine levels with nitisinone treatment were the most commonly reported AEs. Thrombocytopenia and neutropenia may also occur with nitisinone treatment, although no serious sequelae were identified in the studies. Most of the reported serious AEs were considered likely related to the underlying disease and not nitisinone.

The included studies were limited by the open-label design and lack of a direct comparator. Moreover, no absolute or relative measures of effect with formal statistical comparisons were performed on the outcomes between nitisinone plus dietary restriction versus dietary restriction alone, and therefore there is uncertainty as to the magnitude of any benefit with nitisinone as compared with dietary restriction. However, the relatively large difference in survival probabilities (primarily if initiated in those younger than six months) and reduced morbidity as compared with a historical control suggest there is an overall clinically significant beneficial effect with nitisinone in treating patients with HT-1, though the extent to which this would be maintained over a lifetime (approximately 80 years, based on Canadian general population estimates) is associated with uncertainty.

Results of a bioequivalence study demonstrate comparable pharmacokinetic profiles between two nitisinone products, MDK-Nitisinone and Orfadin, in healthy volunteers.
Appendix 1: Patient Input Summary

This section was prepared by CADTH staff based on the input provided by patient groups.

1. Brief Description of Patient Group(s) Supplying Input

Two groups, the Canadian Liver Foundation (CLF) and the Canadian Organization for Rare Disorders (CORD), submitted patient input for this summary.

The CLF is a national charity dedicated to improving the health and outcomes of Canadians living with, or at risk of, various forms of liver disease. The organization funds research programs aimed at discovering the causes, preventive measures, and potential treatments for liver disease. It supports public and professional education programs and patient support programs, as well as fundraising, outreach, and advocacy efforts. The CLF receives program funding in the form of unrestricted educational grants from pharmaceutical companies, but no companies with direct or indirect interest in the drug under review provided any financial support within the last two years. The majority of awareness, education, patient support, and research grant programs is funded by donations from individuals. The group disclosed no conflicts of interest in the preparation of the submission. The information for this submission was collected via a bilingual online questionnaire offered to patients, caregivers, and health care professionals across Canada. Six patients with hereditary tyrosinemia type 1 (HT-1), 36 caregivers, and four health professionals responded to the questionnaire.

CORD is a registered charity that advocates health policies and a health care system that work for those with rare disorders. CORD provides education and resources to patient groups to enable them to better meet their members’ needs. CORD did not receive help outside its patient group in completing, or in collecting and analyzing information for this patient submission. The group did declare a financial payment from Sobi (the manufacturer of Orfadin), in the range of $0 to $5,000 within the last two years. CORD collected information for this submission from interviews with three parents of patients and two metabolic clinic nurses. An online survey was also available to which 12 responded (11 parents and one patient), eight of whom represented Canadian patients. All respondents were diagnosed with HT-1: 75% had acute and 25% had chronic conditions. All forms of nitisinone were included in the CORD submission.

2. Condition-Related Information

HT-1 is a rare, inborn genetic error of metabolism associated with a severe form of liver disease in infancy or early childhood. According to CLF, one in 100,000 individuals is affected globally, but in the Saguenay–Lac-St-Jean region of Quebec, one person in 20 is a carrier and one in 1,846 has HT-1. In its acute form, the disease manifests within the first month of life. Symptoms may include poor weight gain, an enlarged liver and spleen, a distended abdomen, swollen legs, an increased tendency to bleed, and jaundice. Without drug or transplant treatment, death from hepatic failure frequently occurs within three to nine months of birth. The onset of chronic HT-1 is more gradual, and the clinical manifestations are less severe. Common symptoms in these children include enlarged liver and spleen, distended abdomen, poor weight gain, and frequent vomiting and diarrhea. Affected patients usually develop cirrhosis and its complications. Without treatment, these children may develop liver cancer or liver failure and require a liver transplant.
Patient experiences can be categorized either by the form of disease (acute versus chronic) or by the era in which the patient was born (this can relate to the availability of treatment options or to the advent of newborn screening programs). In all cases, it is apparent that patients have the best chance of survival and the fewest long-term complications when they are diagnosed within days of birth and can begin treatment programs immediately upon diagnosis.

The lives of patients and caregivers frequently revolve around the burdens of this disease. Financial, social, and emotional strains may be experienced by the entire family of tyrosinemia patients. Respondents described the impact of HT-1 on their families: “cooking 8 different kinds of meals per day; not able to work on a regular basis; watching children 24/7 to make sure that they don’t eat restricted food; regular hospital visits; lack of a social life — avoiding large family and friends gatherings; financial hardship; building kids’ personality — training them to accept themselves as being different from other children; food training — what to eat and what not to eat; school training — ensuring school environment understands and respects the importance of adherence to regimen….” The demanding treatment regimen, addressed in the next section, represents another set of burdens for patients and caregivers.

3. Current Therapy-Related Information

Prior to the availability of nitisinone in the 1990s, the only treatment options for HT-1 were a strict low-protein diet (low in phenylalanine and tyrosine) and, later, liver transplant. Even on a low-protein diet, some patients struggled to survive awaiting transplant. Without treatment, the disease was almost always fatal before the age of 10. For patients who have undergone liver transplant and who have survived into adulthood, uncertainty of life after transplant is a continued reality.

Most respondents are currently receiving the drug under review (MDK-Nitisinone capsules or Orfadin capsules) or had used it in the past. Nitisinone blocks the breakdown of tyrosine before it can be converted into a harmful product. Patients often respond quickly: blood clotting issues resolve and liver function improves within one week of treatment. Starting nitisinone treatment immediately at diagnosis is a requisite part of the life-saving therapy. Patients experience the benefits of reduced hospitalizations, neurological crises, liver transplants, and other complications, without serious side effects from the treatment. The parents have hope of a future for these children. A pregnant patient from CLF stated that “I started treatment at the age of 5 and before that I experienced the disease with its negative effects with neurological crises and numerous hospitalizations. My life changed completely with the arrival of NTBC in 1993. It has been 22 years since I started taking the NTBC and I have not been hospitalized for the disease since that time.”

While there is unanimous agreement that the nitisinone era has been life-saving and offers the opportunity to lead a more normal life, HT-1 still presents many challenges. Patients must adhere to the strict diet and be monitored regularly for progress. Once a patient is stable, monitoring can decrease in frequency, but the dietary restrictions and medical appointments can be taxing and costly. Another challenge is administering the drug to infants: “It was hard when he was a baby to mix and syringe into his mouth after opening capsules.” A range of experiences is reported in terms of how patients, caregivers, and families are affected by the disease and treatment requirements. Some report little disturbance to their lives, while others experience wide-reaching effects.
Some caregivers feel that life is far from normal, revolving around the demanding treatment schedule and dietary restrictions. Caregivers must ensure that every dose of medication is taken and that every meal is completed. This can be challenging and anxiety-provoking, particularly in newborns and infants, as children enter school (where meal time is less controlled), and during the teenage years. Family and individual social lives may suffer. The financial impact can be significant. At times the caregiver demands are such that parents struggle to maintain a steady job. Patients also live with these restrictions, medical requirements, and complications, which can affect their physical, social, emotional, and financial well-being. Despite treatment, one-third of all respondents in the CORD submission reported that their child was currently experiencing cognitive delay. The submission also highlighted a few minor side effects reported by about half of respondents using Orfadin capsules or oral suspension, including stomach bloating or pain, feeling tired or weak, or loss of appetite or weight. Even if the patient is taking nitisinone, long-term complications of the disease may still occur, most notably the development of liver cancer. However, respondents of both the CLF and CORD surveys generally struggled more with the diet component of the treatment than with the medication.

Finally, there is anxiety about receiving the medication in a timely fashion, as any interruption in treatment has the potential to have serious consequences. The submission from CORD further highlighted the frustration when an uncommunicated switch from one manufacturer of nitisinone to the other was implemented in Canada, and respondents were left wondering and worrying about the efficacy of the drug.

4. Expectations About the Drug Being Reviewed

Two slightly different messages were conveyed by the two patient groups. The somewhat different patient/caregiver experiences and expectations reported in these submissions may have to do with where the respondents live in Canada, as different provinces may offer different options to patients, possibly at different costs and through different access programs.

The CLF submission discussed the current availability of nitisinone through the Health Canada Special Access Programme, with patients receiving their medication from hospital pharmacies. Some respondents are content with this arrangement while others welcome more direct access to their medication through the public drug plans, allowing self-sufficient collection at their local pharmacy, rather than long-distance travel to hospitals.

The CORD submission put more emphasis on unmet needs and future expectations, including the desire for different formulations (e.g., an oral formulation for infants, a tablet rather than capsule option, increased medication stability, and improved taste), less frequent dosing, further research, and a medication that would allow a more normal diet. Finally, while all interview and survey respondents were satisfied with both available versions of nitisinone (MDK-Nitisinone and Orfadin), all also rated the availability of more than one form of nitisinone as “important” or “very important.”

Regardless of the program supporting the availability of nitisinone within Canada, there is a strong and clear message from patients, caregivers, and health care professionals alike. First, the cost to patients should remain low or non-existent. As this is a life-saving therapy, it is imperative to ensure that no patient is left untreated or has to assume an unfair financial burden. Second, universal accessibility and interruption-free availability of nitisinone will be critical (1) during any transition to the public drug plans in Canada and (2) throughout a patient’s lifetime.
## Appendix 2: Literature Search Strategy

### OVERVIEW

<table>
<thead>
<tr>
<th>Interface:</th>
<th>Ovid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Databases:</td>
<td>Embase 1974 to present</td>
</tr>
<tr>
<td></td>
<td>Ovid MEDLINE(R) Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE(R) Daily, and Ovid MEDLINE(R) 1946 to Present</td>
</tr>
<tr>
<td>Note:</td>
<td>Subject headings have been customized for each database. Duplicates between databases were removed in Ovid.</td>
</tr>
<tr>
<td>Date of Search:</td>
<td>September 26, 2017</td>
</tr>
<tr>
<td>Alerts:</td>
<td>Weekly search updates until January 17, 2018</td>
</tr>
<tr>
<td>Study Types:</td>
<td>No search filters were applied</td>
</tr>
<tr>
<td>Limits:</td>
<td>No date or language limits were used</td>
</tr>
<tr>
<td></td>
<td>Conference abstracts were excluded</td>
</tr>
</tbody>
</table>

### SYNTAX GUIDE

<table>
<thead>
<tr>
<th>Syntax</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>/</td>
<td>At the end of a phrase, searches the phrase as a subject heading</td>
</tr>
<tr>
<td>MeSH</td>
<td>Medical Subject Heading</td>
</tr>
<tr>
<td>*</td>
<td>Before a word, indicates that the marked subject heading is a primary topic; or, after a word, a truncation symbol (wildcard) to retrieve plurals or varying endings</td>
</tr>
<tr>
<td>.ti</td>
<td>Title</td>
</tr>
<tr>
<td>.ab</td>
<td>Abstract</td>
</tr>
<tr>
<td>.ot</td>
<td>Original title</td>
</tr>
<tr>
<td>.hw</td>
<td>Heading word; usually includes subject headings and controlled vocabulary</td>
</tr>
<tr>
<td>.kf</td>
<td>Author keyword heading word (MEDLINE)</td>
</tr>
<tr>
<td>.kw</td>
<td>Author keyword (Embase)</td>
</tr>
<tr>
<td>.rn</td>
<td>CAS registry number</td>
</tr>
<tr>
<td>.nm</td>
<td>Name of substance word</td>
</tr>
<tr>
<td>ppez</td>
<td>Ovid database code; Ovid MEDLINE(R) Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present</td>
</tr>
<tr>
<td>oemezd</td>
<td>Ovid database code; Embase 1974 to present, updated daily</td>
</tr>
</tbody>
</table>
MULTI-DATABASE STRATEGY

Embase, Ovid MEDLINE(R)

1. (nitisinon* or nitison* or orfadin* or nityr* or ntbc or SC-0735 or SC0735 or K5BN214699 or 104206-65-7).ti,ab,ot,kf,hw,rm,nm.
2. 1 use ppez
3. *nitisinone/
4. (nitisinon* or nitison* or orfadin* or nityr* or ntbc or SC-0735 or SC0735 or K5BN214699 or 104206-65-7).ti,ab,ot,kw.
5. 3 or 4
6. 5 use oemzd
7. conference abstract.pt.
8. 6 not 7
9. 2 or 8
10. remove duplicates from 9

OTHER DATABASES

PubMed

A limited PubMed search was performed to capture records not found in MEDLINE. Same MeSH, keywords, limits, and study types used as per MEDLINE search, with appropriate syntax used.

Trial registries (Clinicaltrials.gov and others)

Same keywords, limits used as per MEDLINE search.

Grey Literature

Dates for Search: September 2017
Keywords: Drug name, Indication
Limits: No date or language limits used

Relevant websites from the following sections of the CADTH grey literature checklist Grey Matters: a practical tool for searching health-related grey literature (https://www.cadth.ca/grey-matters) were searched:

- Health Technology Assessment Agencies
- Health Economics
- Clinical Practice Guidelines
- Drug and Device Regulatory Approvals
- Advisories and Warnings
- Drug Class Reviews
- Databases (free)
- Internet Search
Appendix 3: Detailed Outcome Data

Table 11: Survival Probabilities After 2, 4, and 6 Years of Treatment With Nitisinone (%)

<table>
<thead>
<tr>
<th>Study population</th>
<th>The NTBC Study (Complementary Analysis)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Survival</td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>2-year</td>
</tr>
<tr>
<td></td>
<td>93</td>
</tr>
<tr>
<td>Start age 0 to 2 months</td>
<td>93</td>
</tr>
<tr>
<td>Start age 0 to 6 months</td>
<td>96</td>
</tr>
<tr>
<td>Start age &gt; 6 months</td>
<td>94</td>
</tr>
</tbody>
</table>

Source: Product monograph of Orfadin.^[28]
Appendix 4: Validity of Outcome Measures

Aim

To summarize the validity of the following outcome measures:

- Succinylacetone (Blood and Urine)
- Plasma Tyrosine

Findings

Succinylacetone (Blood and Urine)

Hereditary tyrosinemia type 1 (HT-1) is caused by a deficiency in fumarylacetoacetate hydrolase (FAH), the final enzyme in the tyrosine catabolic pathway. The substrates upstream of FAH in the metabolic pathway are maleylacetoacetate (MAA) and fumarylacetoacetate (FAA), both of which are reactive, toxic metabolites. When FAH function is lacking, MAA and FAA are not metabolized via the tyrosine catabolic pathway, yet these unstable metabolites are generally not detectable in the urine or blood. In the absence of FAH, FAA and MAA can undergo conversion to succinylacetate (SAA) and, ultimately, to succinylacetone (SA), which is readily detectable in both urine and blood. The FAA derivative, SA, has not been detected in any other diseases, thus it is considered pathognomonic for HT-1. However, two rare FAH mutations have been reported in at least three individuals diagnosed with HT-1 who do not have elevated or detectable levels of SA. Consensus group review in Canada and the US recommends that SA be measured in newborn screening programs to diagnose HT-1, and be further monitored in response to nitisinone treatment. As of 2015, all Canadian provinces and territories, except for New Brunswick, Nova Scotia, and Prince Edward Island, were screening for HT-1 through their newborn screening programs.

Dried blood spots extracted and analyzed by tandem mass spectrometry are the optimal format for newborn screening. A number of different assays are currently in use worldwide and, while studies suggest that these are highly specific and sensitive for HT-1, the nature of these studies is biased, which limits the accurate determination of specificity, sensitivity, positive predictive value, and negative predictive value. Briefly, cut-off values for SA in newborn screening varied from 1.29 μmol/L to 10 μmol/olL. In studies reporting screening experiences, the positive predictive values for the SA test ranged from 66.7% (among ~500,000 screened individuals) to 100% (among ~850,000 screened individuals), but these were associated with large confidence intervals due to the small number of cases. Sensitivity and specificity could not be determined due to lack of follow-up of those with negative screening results. Among case-control studies, the sensitivity (in five studies) and specificity (in four studies) for the test were each reported at 100%. All of the studies evaluating SA assays were at moderate to high risk of bias due to a number of factors. The results of the screening studies were weakened by a lack of adequate follow-up subsequent to a negative screening result and concerns related to the reference standard. The case-control studies present a number of weaknesses including retrospectively specified cut-offs, unblinded assessors, different reference standards across participants within a study, and insufficient reporting of reference standards. Furthermore, each study used unique cut-off values and different recovery methods and collection times,
limiting the comparability of these studies and a comprehensive understanding of newborn SA levels and their relationship to HT-1.\textsuperscript{15} While there is no standard method for newborn HT-1 screening, the available studies do suggest that SA in dried blood spots analyzed by tandem mass spectrometry may provide sufficient precision to differentiate between non-cases and probable cases of HT-1.\textsuperscript{15,48}

Following newborn screening, or clinical presentation with symptoms of HT-1, confirmatory presence of SA in blood, or in urine when blood is not available, is considered diagnostic of HT-1. However, SA testing should be accompanied by further biochemical laboratory tests and corroborated by sequence analysis of the FAH gene before a diagnosis of HT-1 is concluded.\textsuperscript{10}

As the definitive biochemical marker of the HT-1 phenotype, monitoring the decrease or complete disappearance of SA is the standard practice used to confirm a patient’s clinical improvement in response to nitisinone. Absence of SA in blood and urine suggests a complete, or near complete, block of a more proximal step in the tyrosine catabolic pathway, preventing the formation of MAA and FAA and their toxic by-products, SAA and SA. Although no formal minimal clinically important difference exists for SA concentrations in the urine or blood, there is no indication that any level of these metabolites is safe. Thus, clinical consensus is that treatment goals should aim to suppress SA formation.\textsuperscript{10} Multi-year cohort studies suggest that by adopting this course of action, HT-1 symptoms and complications can be slowed or avoided in most patients.\textsuperscript{4,22,23}

SA values quantified from urine and blood will depend on the assay format and sensitivity of the reporting laboratory. The reference limits for normal plasma SA levels may be reported as less than 0.1 μmol/L; normal urine SA levels as greater than 1 mmol/mol creatinine.\textsuperscript{1,2,10,22,23} Less-sensitive assays may report normal SA levels as undetectable.\textsuperscript{10} SA can be volatile, and improper test conditions can prevent detection. Dilute urine, improper handling of urine samples, and certain methods of extraction can lead to false negatives. Thus, an understanding of the assay and proper sample handling and preparation is imperative to interpretation of the results.\textsuperscript{10,15,50,51}

The manufacturer for nitisinone did not provide information regarding the sensitivity, specificity, and positive and negative predictive values for assays to measure SA from dried blood spots, plasma, or urine.

**Plasma Tyrosine**

SA in the blood and urine is the definitive biochemical marker for diagnosis of HT-1.\textsuperscript{10} Tyrosine levels are neither a specific nor a sensitive marker of HT-1, as elevated plasma tyrosine may be identified in cases of hereditary tyrosinemia types 2 and 3 and in transient hypertyrosinemia.\textsuperscript{10,52-54} Furthermore, some newborns with normal tyrosine levels have been diagnosed with HT-1 based on elevated SA concentrations and/or genetic confirmation.\textsuperscript{47,54-56} Neither every country nor region screens for SA, but may measure tyrosine levels. The normal range for plasma tyrosine is about 30 μmol/L to 120 μmol/L.\textsuperscript{6} In newborns the mean tyrosine concentration may be slightly higher.\textsuperscript{57} When elevated tyrosine levels (> 200 μmol/L or 250 μmol/L) are measured, an SA test can confirm or rule out HT-1. In newborn screening programs, both tyrosine and SA tests may be standard practice.\textsuperscript{6,56} However, plasma tyrosine levels are only considered supportive of a diagnosis, as they are non-specific to HT-1.\textsuperscript{10,15,48}
Once a diagnosis of HT-1 is made, and nitisinone treatment and dietary restriction are initiated, plasma tyrosine levels must be monitored to ensure that tyrosine accumulation in the blood, due to inhibition of 4-hydroxyphenylpyruvate dioxygenase in the proximal tyrosine catabolic pathway, does not exceed 500 µmol/L or 600 µmol/L. Nitisinone treatment results in elevated tyrosine levels that can be acceptably managed by instituting a low-protein diet supplemented with controlled amino acid quantities, to limit the amount of tyrosine that builds up in the bloodstream. While it is difficult to maintain a normal tyrosine plasma concentration range while on nitisinone treatment, it is hypothesized that, based on other forms of hypertyrosinemia, elevated tyrosine levels are not responsible for the phenotype of HT-1.

There is no known minimal clinically important difference for tyrosine plasma concentrations, but generally, 200 µmol/L to 600 µmol/L is considered an acceptable range to limit the onset of clinical manifestations of elevated blood tyrosine. Higher plasma tyrosine levels, as observed in HT-2, as well as in HT-1–treated patients who are non-responsive or non-adherent, can result in dermatological, ophthalmological, and possibly neurodevelopmental problems, although exact thresholds and symptoms may be patient-specific. These side effects can generally be avoided and may be reversed by adherence to dietary restriction in combination with nitisinone treatment.
Appendix 5: Bioequivalence Study

Aim
To summarize the details and findings of bioequivalence study 150207.

Findings

Equivalence Study Investigational Plan

Study Design

Study 150207 was a randomized, blinded, one-way parallel bioequivalence study comparing the pharmacokinetics and safety of MDK-Nitisinone (test product) and Orfadin (reference product) following a single 10 mg dose in healthy subjects under fasting conditions.27

The study was conducted in accordance with the recommendations outlined in the Health Canada, Health Products and Food Branch, document Guidance Document: Comparative Bioavailability Standards: Formulations Used for Systemic Effects.65 MDK-Nitisinone or Orfadin was administered orally under fasting conditions.

Inclusion/Exclusion Criteria

Inclusion and exclusion criteria were in accordance with Health Canada's bioequivalence guidance document.65 Briefly, healthy male and female participants between 18 and 55 years of age, with body mass index (BMI) > 18.5 kg/m² and < 30.0 kg/m² and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females were included. Exclusion criteria included a history of significant drug or alcohol abuse within the last year; prescription medication within the last 14 days; significant abnormalities in liver, kidney, hematology laboratory results, or electrocardiogram results; pregnancy or breast-feeding. Participants were to abstain from drugs, alcohol, xanthine, and heavy smoking (more than nine cigarettes per day) throughout the study.27

Pharmacokinetic Parameters

The following pharmacokinetic analyses were calculated by standard non-compartmental methods for nitisinone:27

- AUC₀-tₐₙₐₙₐₙ: area under the concentration-time curve from time zero to the last non-zero concentration
- AUC₀-72: Area under the concentration-time curve from time zero to 72 hours
- AUC₀-∞: area under the concentration-time curve from time zero to infinity (extrapolated)
- Cₘₐₓ: maximum observed concentration
• Residual area: calculated as 100% \((1 – \text{AUC}_{0-\text{tlast}} / \text{AUC}_{0-\text{inf}})\)
• \(T_{\text{max}}\): time of observed \(C_{\text{max}}\)
• \(T_{\frac{1}{2} \text{el}}\): elimination half-life
• \(K_{\text{el}}\): elimination rate constant

**Statistical Analyses**

Summary statistics were calculated for all pharmacokinetic parameters: \(\text{AUC}_{0-\text{tlast}}\), \(\text{AUC}_{0-72}\), \(\text{AUC}_{0-\text{inf}}\), \(C_{\text{max}}\), residual area, \(T_{\text{max}}\), \(T_{\frac{1}{2} \text{e}}\), and \(K_{\text{el}}\).

Ratios of least-square means based on pair-wise comparisons and 90% geometric confidence intervals were calculated for ln-transformed parameters: \(\text{AUC}_{0-\text{tlast}}\), \(\text{AUC}_{0-\text{inf}}\), \(\text{AUC}_{0-72}\), and \(C_{\text{max}}\). Inter-subject coefficient of variation was also determined. Analysis of variance (ANOVA) was performed in Statistical Analysis System, using the General Linear Model Procedure of ln-transformed data for these same parameters. Bioequivalence was established on the basis of the statistical analyses of \(\text{AUC}_{0-72}\) and \(C_{\text{max}}\) exclusively.\(^{27}\)

**Blinding**

All personnel affecting the outcome of Study 150207 were blind to the randomization code until study completion. This included those involved in clinical and analytical phases of the study: collection, monitoring, revision, or evaluation of AEs, and all bioanalyses.\(^{27}\)

**Bioequivalence Study Results**

**Participants and Demographics**

Eighty healthy male and female participants were screened: \(|\) participants were enrolled and 46 were randomized, \(|\) participants to each treatment group (MDK-Nitisinone and Orfadin). Group demographics are summarized in Table 12.
### Pharmacokinetic Parameters

Pharmacokinetic parameters for MDK-Nitisinone and Orfadin are presented in Table 13. Following administration of a single oral dose of nitisinone 10 mg under fasting conditions, the test product, MDK-Nitisinone, demonstrated a mean peak serum concentration ($C_{\text{max}}$) of 1,104 ng/mL, occurring at an approximate mean time of 2.2 hours post-dose ($T_{\text{max}}$), while the elimination half-life ($T_{\frac{1}{2} \text{ el}}$) was 63.7 hours. The reference product, Orfadin, demonstrated the following mean parameters: $C_{\text{max}}$ of [value] at [value], with an elimination half-life of [value].

<table>
<thead>
<tr>
<th>Parameter</th>
<th>MDK-Nitisinone</th>
<th>Orfadin</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_{\text{max}}$</td>
<td>1,104 ng/mL</td>
<td>[value]</td>
</tr>
<tr>
<td>$T_{\text{max}}$</td>
<td>2.2 hours</td>
<td>[value]</td>
</tr>
<tr>
<td>$T_{\frac{1}{2} \text{ el}}$</td>
<td>63.7 hours</td>
<td>[value]</td>
</tr>
</tbody>
</table>

BMI = body mass index; PK = pharmacokinetics; SD = standard deviation.
Source: Clinical Study Report of Study 150207.\textsuperscript{27}
Table 13: Summary Statistics of Pharmacokinetic Parameters

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Bioequivalence Study 150207</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MDK-Nitisinone</td>
<td>Orfadin</td>
</tr>
<tr>
<td>N</td>
<td>Meana</td>
<td>SD</td>
</tr>
<tr>
<td>AUC0-tlast (ng*h/mL)</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>AUC0-inf (ng*h/mL)</td>
<td>76244.45</td>
<td>[ ]</td>
</tr>
<tr>
<td>Residual area (%)b</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>AUC0-72 (ng*h/mL)</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>Cmax (ng/mL)</td>
<td>1103.87</td>
<td>[ ]</td>
</tr>
<tr>
<td>Tmax (h)</td>
<td>2.21</td>
<td>[ ]</td>
</tr>
<tr>
<td>T1/2 el (h)</td>
<td>63.70</td>
<td>[ ]</td>
</tr>
<tr>
<td>Kei (/h)</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
</tbody>
</table>

AUC0-tlast = area under the concentration-time curve from time zero to 72 hours post-dose administration; AUC0-inf = area under the concentration-time curve from time zero to infinity (extrapolated); AUC0-72 = area under the concentration-time curve from time zero to the last non-zero concentration; Cmax = maximum observed concentration; CV = coefficient of variation; Kei = elimination rate constant; PK = pharmacokinetics; SD = standard deviation; T1/2 el = elimination half-life; Tmax = time of observed Cmax.
aArithmetic mean, from measured data uncorrected for potency.
bResidual area: calculated as 100(1 – AUC0-tlast / AUC0-inf).

Source: Clinical Study Report of Study 150207.

Potency

The potency of a 10 mg capsule of the test product, MDK-Nitisinone, was reported to be 1 mg. The reference product, Orfadin hard-gelatin capsule, had a reported potency of 1 mg. Test and reference product potencies fell within 6% of each other. No data or analyses were corrected for potency in Study 150207, and analyses were performed within six months prior to study start date, as specified by Health Canada's bioequivalence guidance document. Potency data are shown in Table 14.

Table 14:

<table>
<thead>
<tr>
<th>Potency Parameters</th>
<th>Test = MDK-Nitisinone (MendeliKABS Laboratories, Canada, nitisinone 1 x 10 mg capsule); Reference = Orfadin, nitisinone 1 x 10 mg capsule).</th>
</tr>
</thead>
</table>
Bioequivalence

Geometric means, ratios of geometric means, and 90% geometric confidence intervals for the pair-wise comparisons of test and reference products of single-dose 10 mg nitisinone, are presented in Table 15, along with associated \( P \) values. Bioequivalence standards were met on natural log-transformed parameters calculated from the measured data, based on 90% confidence interval limits of 80% to 125% for both parameters, \( C_{\text{max}} \) and \( \text{AUC}_{0-72} \):

- \( \text{AUC}_{0-72} \) ratio of geometric means was \[\text{ratio} \times 100\] with a 90% confidence interval of \[\text{CI}\].
- \( C_{\text{max}} \) ratio of geometric means was \[\text{ratio} \times 100\] with a 90% confidence interval of \[\text{CI}\].

<table>
<thead>
<tr>
<th>Parameters(^a)</th>
<th>Geometric Mean</th>
<th>% ratio of geometric means(^b)</th>
<th>90% geometric confidence interval(^c)</th>
<th>Inter-subject CV %</th>
<th>( P ) value(^d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test(^e)</td>
<td>Reference(^e)</td>
<td>Test - Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \text{AUC}_{0-\text{tlast}} ) (ng*h/mL)</td>
<td>[\text{mean}]</td>
<td>[\text{ratio} \times 100]</td>
<td>[\text{CI}]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \text{AUC}_{0-\text{inf}} ) (ng*h/mL)</td>
<td>7355.84</td>
<td>[\text{ratio} \times 100]</td>
<td>[\text{CI}]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \text{AUC}_{0-72} ) (ng*h/mL)</td>
<td>1067.19</td>
<td>[\text{ratio} \times 100]</td>
<td>[\text{CI}]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>( C_{\text{max}} ) (ng/mL)</td>
<td>[\text{mean}]</td>
<td>[\text{ratio} \times 100]</td>
<td>[\text{CI}]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\( \text{AUC}_{0-72} \) = area under the concentration-time curve from time zero to 72 hours; \( \text{AUC}_{0-\text{inf}} \) = area under the concentration-time curve from time zero to infinity (extrapolated); \( \text{AUC}_{0-\text{tlast}} \) = area under the concentration-time curve from time zero to the last non-zero concentration; \( C_{\text{max}} \) = maximum observed concentration; CV = coefficient of variation.

\( ^a \) From measured data uncorrected for potency.
\( ^b \) Calculated using least-squares means for ln-transformed data according to the formula: \( e^{(\text{difference})} \times 100 \).
\( ^c \) 90% geometric confidence interval using ln-transformed data.
\( ^d \) \( P \) values for treatment effect derived from ANOVA performed on ln-transformed data.
\( ^e \) Test = MDK-Nitisinone (MendeliKABS Laboratories, Canada, nitisinone 1 \times 10 mg capsule); Reference = Orfadin, nitisinone 1 \times 10 mg capsule.

Source: Clinical Study Report of Study 150207.\(^{27}\)

Safety/Harms

A total of \[\text{participants}\] in each treatment group experienced \[\text{treatment-emergent adverse events}\] after receiving the single-dose of study medication (Table 16). The most common adverse event was \[\text{adverse event}\], reported by \[\text{participants}\]. All treatment-emergent adverse events were mild and all were resolved by the end of study. No serious adverse events or deaths occurred.\(^{27,66}\)
Table 16:

<table>
<thead>
<tr>
<th></th>
<th>Test Product</th>
<th>Reference Product</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TEAE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Number</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NR = not reported; TEAE = treatment-emergent adverse event.

*Number of subjects experiencing TEAEs presented by treatment: a participant could contribute only once to each of the incidence rates, regardless of the number of occurrences.

Source: Clinical Study Report of Study 150207.27

**Summary**

The test product, 10 mg capsule of MDK-Nitisinone, met all potency and bioequivalence requirements to be declared equivalent to reference product, Orfadin, based on Health Canada guidelines.28 No safety signals emerged from this study.
References


19. MDK-Nitisinone: 2 mg, 5 mg, 10 mg capsules [product monograph]. Saint-Hubert (QC): MendeliKABS Inc.; 2016 Sep 19.

20. CDR submission:MDK-nitisinone, 2 mg, 5 mg, 10 mg capsules. Company: MendeliKABS Inc. [CONFIDENTIAL manufacturer's submission]. Saint-Hubert (QC): MendeliKABS Inc.; 2017 Oct 12.


28. Orfadin (nitisinone): 2 mg, 5 mg, 10 mg and 20 mg capsules [product monograph]. Stockholm: Swedish Orphan Biovitrum AB (publ); 2017 Nov 10.


